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Abstract
Cell transplantation can be considered a regenerative therapy, an intervention
which attempts to replace or restore the function of compromised tissue by harnessing
innate properties of cells that cannot be replicated artificially. For such therapies to
succeed, it will be necessary to understand and closely match the physiological
conditions that govern cell behaviors in vivo. One important factor is low oxygen
tension, termed hypoxia, which is often overlooked in vitro.

Because oxygen

insufficiency can lead to cell death, hypoxia has traditionally been viewed as a negative
condition.

However, hypoxia can also serve as a potent regulator of crucial cell

behaviors involved in normal development, adaptation, and regeneration through
transcriptional activity of hypoxia-inducible factors (HIFs). Characterizing HIF activity,
especially in three-dimensional tissues which can experience oxygen heterogeneities,
will be useful in investigating how culture parameters impact local microenvironmental
conditions to affect cell behavior.
In the present work, a novel fluorescent reporter system was used to detect
cellular HIF activity in islet-like clusters of pancreatic β-cells and adipose-derived stem
cell (ADSC) spheroids, two cell systems used in transplantation therapies. Fluorescent
signaling was observed in cultures incubated in reduced oxygen conditions and in large
cultures, indicating the development of tissue size-dependent oxygen gradients. HIF
activity could be monitored in the same samples over time and could be correlated to
v

other cell behaviors. In β-cells, signal was observed in all clusters incubated in 1% or 2%
oxygen and in the center of large clusters (>300μm) incubated in 20% oxygen. In
clusters that exhibited HIF activity, insulin secretion and cluster morphology were
severely impaired. In ADSC spheroids, both reduction of external oxygen concentration
and an increase in spheroid size increased HIF activity.

Moderate HIF activity

corresponded with increased vascular endothelial growth factor (VEGF) secretion from
spheroids, while intense HIF activity corresponded with regional reduction of cell
viability; therefore, an optimal size for VEGF secretion could be demonstrated.
Altogether, the HIF reporter system represents a useful tool in monitoring cellular
hypoxia so that culture parameters such as external oxygenation and culture size can be
properly considered in order to guide desired cell behaviors in cell transplantation.
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Introduction
This dissertation is concerned with presenting and discussing experimental data
which contributes novel findings to the field of cell transplantation. Specifically, results
from the included studies provide a better understanding of how hypoxia develops
within 3-dimensional (3D) cultures of pancreatic β-cells and adipose-derived stem cells
(ADSCs) and how knowledge of this hypoxic status can be used to rationally direct
desired cell behaviors (insulin secretion and VEGF secretion, respectively) to improve
outcomes in transplantation therapies intended to restore lost tissue function. The
structure of this dissertation, then, is intended to both communicate peer-reviewed
results from several separate studies and to make clear the underlying impetus by which
they are unified. The document is structured in the following manner:
•

Chapter 1 consists of a literature review intended to develop a framework
explaining why the research was undertaken. This includes relevant historical
studies, recent findings and advancements in the field, and identification of
areas in which the current knowledge appears to be incomplete. Specifically, the
essential role of oxygen as a both a nutrient and as a cell signaling molecule is
first discussed. Next, the mechanism of hypoxia-mediated regulation of cell
behavior is explained, and it is suggested that rational control of culture
parameters can be used to regulate hypoxic status, thus driving desired cell
function. A novel approach to identifying cellular hypoxia is also advocated.
1

Finally, the importance of hypoxic status is considered in two specific cell
systems which exhibit potential usefulness in transplantion therapies: islet-like βcell clusters and ADSC spheroids. The advantages of tracking hypoxia by use of a
novel reporter system as well as the potential benefits of characterizing hypoxia
in these two systems are highlighted.
•

Chapters 2-4 are research studies that have been published or submitted for
publication in peer-reviewed research journals. These chapters each include a
brief introduction, description of experimental methods and design, study
results, and discussion of the findings. Section, figure, and reference numbering
has been altered to conform to the formatting of this dissertation. Chapter 2
reports on the use of the hypoxia reporter in encapsulated islet-like clusters of βcells of different sizes cultured in 20% or 1% oxygen. Chapter 3 compares
hypoxic status, function, and viability of encapsulated clusters of the same size
cultured in 20%, 2%, or 1%. Chapter 4 reports how overall hypoxic status of
ADSC spheroids, as indicated by the reporter, can be intentionally affected by
spheroid size and culture oxygenation in order to direct optimal secretion of
proangiogenic growth factors from the cells.

•

Chapter 5 discusses the overall findings of the previous three chapters, tying
together the results and making an argument for the importance of considering
oxygen tension in cell-based therapies. The novel results of these studies as well
as their contribution to the advancement of β-cell and ADSC transplantation are
presented.
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Chapter 1
Literature Review
1.1 Oxygen’s Role as a Nutrient
Oxygen is an abundant element in nature, existing commonly as colorless,
odorless dioxygen gas (O2), or forming oxides with most other elements. Estimates
suggest that oxygen presently accounts for roughly 49% (wt.) of Earth’s crust and 21%
(vol.) of Earth’s atmosphere [1 Duursma and Boissan, 1994]. Furthermore, molecular
oxygen has been present in the environment, at varying levels, for the majority of the
time span over which life has been evolving [2 Castresana 1995],[3 Dismukes 2001],[4
Kump 2008],[5 Stamati 2011]. From its ubiquity, it is not surprising, then, that oxygen
plays an integral role in the biochemical processes of most known species. While
certain unicellular organisms with ancient evolutionary origins have retained the
capability to survive without oxygen, most other unicellular organisms, and virtually all
multicellular ones, are dependent upon oxygen for survival. Indeed, incorporation of
oxygen into biotic biochemistry may have been a prerequisite for the development of
metazoan life [3 Dismukes 2001],[5 Stamati 2011]. The importance of oxygen to human
biology, for instance, is evidenced by the complex mechanisms that have evolved to
facilitate its availability: respiratory organs (lungs) to take in oxygen, carrier molecules
(hemoglobin) to bind it, and a circulatory system (heart and blood vessels) to distribute
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it throughout the body. In this regard, oxygen can be considered a nutrient, a chemical
used in an organism’s metabolism that is required to sustain its life and which must be
taken in from its external environment [6 Whitney 2005].

1.1.1 Aerobic Respiration
In living organisms, the presence of oxygen allows for increased efficiency in
energy production. Organisms that do not utilize oxygen for energy production depend
solely upon the process of glycolysis for the direct formation of adenosine triphosphate
(ATP) and are termed “anaerobes”. Anaerobes are typically unicellular and prokaryotic.
Alternatively, aerobes use oxygen as the final electron receptor in the process of
oxidative phosphorylation, a series of reactions that generate 16-18 times more ATP
than glycolysis. In aerobic cells, mitochondria, the organelles in which the oxidative
phosporylation process occurs, can account for 85-90% of cellular oxygen consumption
[7 Solaini 2010].
In the process of oxidative phosphorylation, pyruvate, the product of glycolysis,
is further broken down in the citric acid cycle to produce more ATP as well as the
reduced form of the molecules nicotinamide adenine dinucleotide (NADH) and flavin
adenine dinucleotide (FADH2), which act as energy carries (Figure 1.1). NADH and
FADH2 donate electrons to the electron transport chain (ETC), a series of membraneassociated protein complexes that are sequentially reduced by the electrons, resulting
in protons being pumped out of the inner mitochondrial compartment against their
concentration gradient. The electrons are finally passed to the enzyme, cytochrome-c
oxidase (COX), which uses four electrons to catalyze the reduction of one molecule of O2
4

to two molecules of water [8 Brunori 1987]. The proton gradient generated by the ETC
is used by the transmembrane protein complex, ATP synthase, to generate ATP (Figure
1.2). It is estimated that nearly 40% of the energy represented in the oxidation of
glucose is converted to energy in the form of ATP [9 Bergamini 2004], making aerobic
respiration a highly efficient biological reaction.

Figure 1.1 Production of energy-carrying molecules in
aerobic cellular respiration.
Comparison of ATP
production in the aerobic and anaerobic processes is also
shown.
(ADP: adenosine diphosphate; CO2: carbon
dioxide; acetyl CoA: acetyl co-enzyme A)
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Figure 1.2 Schematic of the ETC and production of ATP by
proton motive force. NADH and FADH2 initially donate
electrons to different complexes in the ETC, resulting in
the transfer of a different number of protons for the two
molecules.

1.1.1.1 Aerobic Respiration and Organismal Complexity
The energy yield from anaerobic respiration is relatively small in comparison to
aerobic respiration. This energy limitation necessarily limits the diversity of molecules
that can be produced in anaerobic species, and, in turn, restricts their potential size and
complexity. Raymond and Serge predicted that at least 1000 metabolic reactions which
occur in aerobic metabolism cannot occur under anaerobic processes [10 Raymond
2006]. Specifically, these tend to be synthesis reactions of larger, more hydrophilic
macromolecules.

Additionally, certain molecules, such as sterols, that are essential to

complex, compartmentalized cells, require oxygen for their biosynthesis and are thus
typically lacking in anaerobic organisms [11 Summons 2006]. Furthermore, elevated
metabolic levels resulting from aerobic respiration have been suggested to have
contributed to the development of nuclear signaling pathways in eukaryotes, as many
nuclear factors are products of respiration [12 Jiang 2010]. Thus, it is clear that the rise
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of atmospheric oxygen and the emergence of aerobic metabolism were critical to the
evolution of complex metazoans whose energy demands cannot be met by glycolysis
alone [5 Stamati 2011],[12 Jiang 2010],[13 Thannickal 2009]. In fact, oxygen is noted to
be among the most commonly-used molecules in the metabolic and biosynthetic
processes of multicellular animals [10 Raymond 2006].

1.1.1.2 Aerobic Respiration and Reactive Oxygen Species
Evolution of the ability to use oxygen in the production of energy was a boon to
organismal complexity.

However, use of oxygen in metabolism presents a set of

challenges for aerobic life forms. The large energy release from the reduction of O2 to
water is harnessed during oxidative phosphorylation in a series of less energetic
reduction reactions in the ETC.

Electron “leak” during these steps can result in

premature and incomplete reduction of O2 and formation of several different oxygen
metabolites such as hydrogen peroxide (H2O2), superoxide anions (·O2-), or hydroxide
radicals (HO·). These products, known as reactive oxygen species (ROS), are significantly
less stable than molecular oxygen and interact with other biomolecules much more
readily than O2.
At least nine mitochondrial enzymes in the ETC have been found to measurably
contribute to ROS production in mammalian cells [14 Andreyev 2005]. In fact, it has
been estimated that 2-3% of the molecular oxygen utilized by mitochondria in oxidative
phosphorylation is incompletely reduced [15 Gibson 2008]. If not neutralized, excessive
ROS levels can be extremely toxic to a cell. ROSs have the ability to damage lipids,
proteins, and deoxyribonucleic acids (DNA), among other cell constituents [9 Bergamini
7

2004],[16 Chance 1955]. Furthermore, oxidative damage by ROSs to certain enzyme
complexes involved in the ETC can cause an increased generation of more ROSs in a
feed-forward manner. Cellular damage caused by ROSs is collectively referred to as
“oxidative stress” and can result in cell death. The negative impact that ROSs can have
on cellular function can be implied from the considerable number of protective
mechanisms that aerobic cells have developed for detoxifying ROSs or mitigating their
damage [14 Andreyev 2005].

1.1.2 Hypoxia
In 1772, Joseph Priestley showed that depletion of an essential element in air by
a mouse in a sealed glass jar resulted in the animal’s death, and that a plant placed in
the jar could restore the air’s vitality [17 Priestley 1772]. The element was subsequently
isolated and identified as oxygen [18 Lavosisier 1789]. The word “hypoxia” (“hypo” –
low or less, and “oxia” – referring to oxygen), then, denotes a state of reduced
oxygenation within a biotic environment, often used to mean “oxygen insufficiency”. In
humans, some common causes of hypoxia within bodily tissues include environmental
limitation (thin air), respiratory disorder, blood disorder (anemia), vascular
damage/occlusion, and elevated metabolic use (exercise). From Priestley’s experiment,
it is clear that the dire, organismal-level effects of hypoxia have long been known.
Different species can exhibit different tolerances to hypoxia.

For instance,

loggerhead turtles, marine reptiles, have been found to dive underwater for up to seven
hours before resurfacing [19 Hochscheid 2005], while sperm whales, marine mammals,
can dive for thirty minutes to an hour [20 Watkins 2002]. For many common terrestrial
8

mammals, including humans, the survival time without oxygen is generally found to be
4-6 minutes. (Indeed, Irving estimated that the maximal theoretical store of oxygen in
an average adult male would be completely consumed by resting metabolism in no
more than 11 minutes [21 Irving 1939].) Resistance to hypoxia also varies among
different types of tissue, depending largely upon their metabolic activity and energy
requirement. For instance, the estimated survival times of different human tissues
without oxygen vary widely: brain, < 3 min.; kidney and liver, 15-20 min.; skeletal
muscle, 60-90 min.; vascular smooth muscle, 24-72 hrs.; hair and nails, several days [22
Leach 1998]. However, no matter the cellular or organismal tolerance for hypoxia, all
forms of life that are dependent upon aerobic respiration succumb to oxygen
deprivation of sufficient severity or duration.

1.1.2.1 Hypoxia: Notes on Terminology
The term “hypoxia” is applied somewhat ambiguously in the biomedical
literature, describing either an oxygen range, typically 0% – 5% O2, or a comparative
oxygen tension that is below the physiological norm for a given tissue. The difference is
subtle yet relevant, as the native oxygen environment can vary significantly between
different tissues in the body. For instance, from Table 2.1 it can be seen that some
tissues constantly reside in an environment that is traditionally considered hypoxic,
while others can experience a significant reduction in oxygen from normal levels while
remaining above an oxygen partial pressure (pO2) of 5% [23 Carreau 2011],[24 Fermor
2007].

9

Table 1.1 Normal pO2 values reported in different
human tissues.

Tissue
Articular Cartilage
superficial
deep zone
Bone Marrow
Brain

mmHg
53
<7.6
52-55
24-48

pO2
%
7
<1
6.8-7.2
3.2-6.3
(>4.6 ensures
normal function)

Intestine
small bowel wall
61
8.0
solon wall
34
4.5
Kidney
cortex
50
6.6
medulla
10-20
1.3-2.6
Liver
31-42
4.1-5.5
Lungs
alveolar surface
100-120
13.2-15.8
Muscle
3.3
biceps
25
34
4.5
deltoid
gastrocnemius
29
3.8
quadriceps femoris
32
4.2
tibial muscle
21
2.8
Skin
1.1
superficial region
8
24
3.2
dermal papillae
sub-papillary plexus
35
4.6
Compiled from references in 24 Carreau 2011 and 24 Fermor
2007.

Due to such imprecise terminology, attempts to clarify the language have been
sporadically, though increasingly, seen.

The more accurate terms “atmospheric

normoxia” and “hyperoxia” have been used to describe atmospheric oxygen pressure,
while “physiological normoxia”, “physioxia”, and “in situ normoxia” have been used to
express normal physiological oxygen pressure [23 Carreau 2011],[25 Ivanovic 2009]. For
such discriminating authors, “hypoxia” is reserved to denote an abnormally reduced pO2.
Such descriptions are further complicated, however, by the somewhat variable reports
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of the “physionormal” pO2 range, e.g. 3-10% [23 Carreau 2011], 2-9% [26 Simon 2008],
3-5% [27 Semenza 2012a], 1-14% [5 Stamati 2011]. Additionally, normal tissue oxygen
pressure can vary from individual to individual and can be affected by various activities.
In any case, the traditional use of “normoxia” to represent atmospheric oxygen pressure
(21%) and “hypoxia” to represent oxygen pressures below 5% persists in the vast
majority of the published literature.
That conditions which are traditionally viewed as “hypoxic” can be both
physionormal and pathological depending upon the local microenvironment is a central
theme of the present work. In either case, oxygen tension acts as a stimulus, affecting
cell behavior and function. Therefore, this work will attempt to characterize “hypoxia”
in such terms.

1.1.2.2 Hypoxia: Effects of O2 Limitations on Aerobic Respiration
Lack of oxygen is lethal to cells that rely on aerobic respiration, though the
process of hypoxic cell death is not always straightforward. Some cellular effects of
hypoxia can include dramatically reduced protein production and turnover,
mitochondrial derangement, loss of osmotic balance, increased oxidative stress, and cell
death by necrosis, apoptosis, or autophagy [7 Solaini 2010],[28 Hochachka 1996],[29
Shimizu 1996], [30 Zhang 2008],[31 Azad 2008],[32 Kumar 2010]. As O2 is required to
accept electrons at the end of the ETC, it would be reasonable to assume that a paucity
of oxygen would result in the dysfunction of oxidative phosphorylation. Indeed, in a
traditional view, hypoxic cell death proceeds as follows: inhibition of the ETC, cessation
of ATP production, depletion of ATP pools through utilization in cellular processes,
11

failure of membrane ion pumps, loss of osmotic balance, and, finally, necrotic cell death.
However, more thorough investigations over the past several decades have found that
disruption of the ETC due to oxygen limitation is not normally the precipitating cause of
death in hypoxic cells.
By examining the relationship between oxygen concentration and electron flux
in isolated mitochondria, it was found that COX activity did not become oxygen limited
until oxygen concentrations fell below <0.1% [33 Wilson 1979],[34 Erecinska 1982],[35
Rumsey 1990]. In other words, the ETC could still function to produce ATP even at
oxygen concentrations well below the levels of physiological hypoxia. Interestingly,
global cellular responses to hypoxia are often seen at oxygen concentrations in the
range of 1-3% O2, higher than the concentration at which oxygen becomes limiting for
ETC function [36 Schumacker 1993] [37 Budinger 1996],[38 Chandel 1997],[39 Budinger
1998]. Such changes include reduction of energy-intensive processes, activation of
glycolytic pathways, and changes in mitochondrial respiratory rate.

This implies,

somewhat counter intuitively, that instead of oxygen-limited mitochondrial function
altering cellular function, altered cell function triggered by hypoxia seems to alter
mitochondrial function. Indeed, it was found that cellular ATP utilization is the primary
factor influencing respiration rate in most cells, accounting for up to 50% of the control
over the process, while the ETC account for only 0-15% [40 Brown 1990a],[41 Brown
1990b].
Suppression of mitochondrial oxygen consumption in the range of 1-3% O2 is
referred to as oxygen conformance and is a well-documented phenomenon [28
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Hochachka 1996]. When this occurs, an increase in glycolytic respiration is usually seen.
Though much less efficient than the aerobic process, glycolysis can proceed quickly and
makes ATP availably directly into the cytoplasm. Thus it can provide a significant
amount of ATP for a cell in the short term. However, glycolysis also uses glucose much
more rapidly that aerobic respiration. In conditions where both oxygen and nutrient
availability are limited (such as ischemia, or severe hypoxia in cells with a high energy
demand) glycolytic glucose insufficiency can result in ATP depletion, loss of osmotic
balance, and necrosis, as predicted by the traditional view of hypoxia [42 Eguchi 1997].
That the oxygen-dependent chemical reaction in the aerobic metabolic pathway
is not oxygen-limited when cells begin to exhibit a response to hypoxia indicates that
nutritional oxygen (i.e. oxygen as a simple metabolic substrate) cannot be responsible
for the changes in cell behavior. However, such adaptive behaviors are clearly a direct
response to changes in oxygen concentration, implying that oxygen must be involved in
affecting behavior by some other oxygen-sensitive pathways. Thus, it is clear that
beyond simply serving as a nutrient, oxygen must also play a role in cell signaling events.
This role, and the mechanisms by which it is facilitated, will be discussed in the following
section.

1.2 Oxygen’s Role in Cell Signaling
The ability of cells to react/adapt to low oxygen tension implies the existence of
cellular mechanisms for sensing oxygen and subsequently transmitting signals to alter
cell behavior. One of the earliest examples of such signaling to be discovered was the
ability of low pO2 to alter the ionic conductance of cells within the carotid body in the
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carotid artery, triggering electrical signaling of the central nervous system to affect
breathing and arterial tone [43 López-Barneo 1988]. Another such oxygen-sensitive
response is the upregulation of erythropoietin (EPO), the hormone responsible for red
blood cell maturation, in oxygen deficient kidney and liver cells, also investigated in the
mid eighties [44 Bondurant 1986],[45 Schuster 1989]. Following these observations, the
subsequent, pervading assumption held that oxygen sensing in the body was
accomplished primarily by such variously-distributed, specialized cells. However, work
in the early 1990’s by the Semenza group uncovered a universal oxygensensing/signaling mechanism common to all nucleated cells in humans and well
conserved in most vertebrates. This mechanism was determined to be the primary
means by which all cells regulate oxygen homeostasis, adapting energy consumption to
oxygen supply and avoiding excessive ROS formation. Furthermore, continued research
over the ensuing two decades has slowly revealed how low oxygen tension and the
cellular behaviors that it drives are an ordinary and indispensible part of many cell
functions and of normal organismal development.

As tissue engineering and

regenerative medicine perspectives take an increasingly prominent position in the
advancement of medical therapies, it will be essential to consider oxygen’s role not only
as a nutrient but as a potent signaling molecule, influencing a myriad of cell behaviors.

1.2.1 Hypoxia Inducible Factors: The Master Regulators of Response to Hypoxia
Hypoxia-inducible factor-1 (HIF-1), first identified by Semenza and Wang in 1992
[46 Semenza 1992], is an oxygen-regulated transcription factor, commonly referred to
as the master regulator of hypoxia. Since its discovery, two other HIF-family proteins,
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HIF-2 and HIF-3, have been identified. Beyond simply helping cells cope with reduced
oxygenation, HIF proteins have been found to drive important cell behaviors involved in
embryonic development, cell commitment and maturation, and healing, as well as
pathologies such as cancer.

As HIF-proteins appear to regulate the majority of

observable changes in cell behavior in response to reduced oxygen tension, the
presence of cellular HIF activity has the potential to be more instructive regarding cell
behavior than measuring local oxygen concentration.

1.2.2 HIFs: Discovery
The observation of oxygen conformance in mitochondria suggested a
widespread mechanism of oxygen sensing common to all cells [28 Hochachka 1996].
Using DNase I protection assays to examine the mechanism of EPO responsiveness to
oxygen in human hepatoma cells, Semenza et al. first identified a 256-base-pair region
in the EPO gene that bound at least two anemia-induced nuclear factors and which
conferred hypoxia inducibility when transiently expressed in other genes [47 Semenza
1991].

Further examination of this region delineated the essential 50-nucleotide

enhancer sequence, which was termed the hypoxia responsive element (HRE) and
identified a nuclear factor, HIF-1α, which exhibited hypoxia-inducible binding to the HRE
[46 Semenza 1992]. In the hepatoma cells, presence of a functional HRE resulted in a
seven-fold increase in EPO production in response to hypoxia (1% O2).
Maxwell et al. soon showed that the HRE elicited hypoxia-responsive
transcription in a number of other cell types as well [48 Maxwell 1993]. Human fetal
lung fibroblasts, human skin fibroblasts, human monocyte/macrophage cells, monkey
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renal fibroblasts, pig retinal epithelial cells, rat aortic endothelial cells, Chinese hamster
lung fibroblasts, Chinese hamster ovary cells, mouse renal adenocarcinomas, and mouse
erythroleukemias were transiently transfected with a plasmid containing the HRE
enhancer fused to a broadly active promoter and the α1-globin gene as a reporter. In
1% oxygen, 11 of the 12 tested lines demonstrated a 3- to 11- fold induction of α1-globin
production, similar to the original observations in hepatomas [48 Maxwell 1993]. This
implied that the same hypoxia-responsive nuclear factor responsible for HRE binding
and EPO upregulation in hepatomas must be present in a range of cell types and may
represent a widespread mechanism for response to hypoxia.

Indeed, Wang and

Semenza observed that a number of mammalian cell types which did not express the
EPO gene still exhibited binding of HIF-1 to DNA and that the binding site was the same
conserved HRE sequence [49 Wang 1993a]. Weiner et al. later demonstrated HIF-1
expression in every mammalian tissue they tested: brain, kidney, liver, heart, placenta,
pancreas, and skeletal muscle tissue in mice, rats, and humans [50 Weiner 1996].
Subsequent investigation has found that HIF-1 and its oxygen-sensitive regulator
mechanism are conserved in all aquatic and terrestrial vertebrates [51 Rytkönen 2011].

1.2.3 HIFs: Structure
HIF-family proteins are heterodimeric transcription factors comprising a
constitutively-expressed and stable β subunit and one of three constitutively-expressed
α subunits, subject to post-transcriptional, oxygen-dependent regulation. The β subunit
is also known as the aryl hydrocarbon receptor nuclear translocator (ARNT). The α
subunits are termed HIF-1α, HIF-2α, and HIF-3α, with HIF-1α being the most prominent
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and most well-studied (though the importance of non-redundant activities regulated by
HIF-2α is becoming more well-elucidated).
Both α and β subunits have been identified as members of the basic Helix-LoopHelix PER-ARNT-SIM (bHLH-PAS) family of transcription factors [52 Wang 1995]. Kewley
et al. review the biology of this family of proteins [53 Kewley 2004].

bHLH-PAS

transcription factors are often signal-regulated and bind to non-traditional variants of
the classic E-box enhancer. In the case of HIF heterodimers, the specific recognition
sequence is the HRE found in the promoter region of target genes. The conserved
portion of this recognition sequence is 5’-(A/G)CGTG-3’ [54 Semenza 1996]. The PAS
domain is named for three proteins in which the domain was originally identified: Period
Circadian Protein (PER), ARNT, and Single-Minded Protein (SIM). Signals mediated by
PAS domains in various organisms include redox state, xenobiotic metabolism, light
detection, and oxygen balance [55 Taylor 1999].
Members of the bHLH-PAS family must dimerize to become functional and are
defined by two major domains: 1) a bHLH domain near the N-terminus, termed the Nterminal transactivation domain (NTAD), responsible for nonspecific dimerization [56
Murre 1989],[57 Reisz-Porszasz 1994],[58 Ema 1996],[59 Jiang 1996a],[60 Kobayashi
1997], with the basic region being the site of DNA binding [61 Ferré-D’Amaré]; and 2) a
PAS homology domain which establishes dimerization partner specificity and target
gene specificity [55 Taylor 1999],[62 Pongratz 1998],[63 Crews 1999]. In addition, HIF-α
subunits contain an oxygen-dependent degradation domain (ODD), while HIF-1α and
HIF-2α contain a C-terminal transactivation domain (CTAD) which interacts with
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transcriptional co-activators to help initiate transcription [64 Jiang 1997],[65 Huang
1998],[66 Ema 1999],[67 O’Rourke 1999],[68 Maynard 2003]. While HIF-β is known to
interact with a number of other bHLH-PAS proteins, HIF-1α dimerizes almost exclusively
with HIF-β. In humans, HIF-1α is encoded by the HIF1A gene, HIF-2α is encoded by the
endothelial PAS domain protein 1 (EPAS1) gene, and HIF-3α is expressed as multiple
splice variants of the HIF3A gene [52 Wang 1995], [68 Maynard 2003],[69 Makino 2002].

1.2.4 HIFs: Transcriptional Activity
HIF-α is constitutively produced in the cytoplasm where it is rapidly degraded in
the presence of oxygen. When oxygen concentrations drop and HIF-α levels rise, the
protein is translocated to the nucleus where it is free to dimerize with HIF-β [70 Chilov
1999]. Translocation may be partially dependent upon mitochondrial succinate [71
Brière 2005]. In the nucleus, the HIF heterodimer binds to HRE sequences in target
genes and recruits the CREB-binding protein/p300 (CBP/p300) transcriptional
coactivator complex to initiate transcription [66 Ema 1999],[72 Arany 1996],. Both HIF
stability and the ability of HIF dimers to interact with the CBP/p300 complex are
regulated in an oxygen-dependent manner.

1.2.5 HIFs: Regulation
Following its discovery, it was known that HIF-1α was regulated by oxygen but
was not itself responsible for oxygen sensing. Due to their direct chemical interactions
with molecular oxygen, COX and heme proteins were first suggested as likely oxygensensing candidates [28 Hochachka 1996].
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(It was later shown that HIF-α can be

stabilized even in the absence of functional ETC machinery, including COX [73 Brunelle
2005].) In 2001, however, it was discovered that a member of the conserved family of
prolyl-4-hydroxylases (PHDs) [74 Epstein 2001],[75 Bruick 2001], specifically prolyl 4hydroxylase 2 (P4H2) [76 Berra 2003], was the cellular oxygen sensor and regulator of
oxygen-dependent degradation of HIF-α. Since then, several other mechanisms of HIF
regulation, either directly or indirectly dependent on oxygen, have been identified or
suggested.

1.2.5.1 Regulation of HIF-α Protein Stability
Activation of HIF-1 is oxygen-dependent and is regulated by stability of the HIF1α protein subunit. Both HIF-1α and HIF-1β messenger ribonucleic acids (mRNAs) are
constitutively expressed intracellularly, but HIF-1α protein levels are nearly
undetectable in normoxic cells, even when HIF-1α is overexpressed. In hypoxic cells,
high levels HIF-1α are observed, but HIF-1β levels are unaffected. Both intracellular
levels of HIF-1α and DNA binding of HIF-1 rapidly decrease upon re-introduction to
normoxia [77 Huang, 1996].
Examination of HIF-1α by Ratcliffe et al. revealed a region of the protein
between amino acids 530 and 652, the ODD, which conferred oxygen-dependent
repression when transferred to a reporter gene system [78 Ratcliffe 1998]. They
suggested that the mechanism of regulation may be mediated by proteolytic
degradation. It was later found that P4H2 was responsible for hydroxylating HIF-1α
within this region [76 Berra 2003]. Specifically, it was shown that P4H2 hydroxylates
two key proline residues, proline 564 [79 Ivan 2001] and proline 402 [80 Masson 2001],
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in the ODD which allows for its recognition by the E3-ubiquitin ligase complex. Activity
of the HIF PHD family of enzymes is dependent on Fe2+, α-ketoglutarate (2-oxoglutarate),
and ascorbic acid as co-factors and O2 as a cosubstrate. In the case of HIF-1α, P4H2
catalyzes a dioxygenase reaction in which one oxygen atom is inserted into the proline
residue and the other is inserted into α-ketoglutarate to form succinate and CO2 [81
Schofield 2004]. Thus P4H2 serves as the global, cellular oxygen sensor. In the presence
of oxygen, P4H2 mRNA is upregulated [74 Epstein 2001] and the hydroxylation reaction
with HIF-1α proceeds. When oxygen is limited, the reaction does not take place and
HIF1α is not hydroxylated. In addition, the protein, OS-9 can interact with both HIF-1α
and P4H2 to promote degradation [82 Baek 2005]. The requirement of Fe2+ as a
cofactor explains the ability of iron chelating agents, such as cobalt chloride and
desferoxamine, to induce a hypoxic response in cells.
Hydroxylated HIF-1α is recognized by the von Hippel-Lindau tumor suppressor
protein (pVHL), the β-domain of which interacts with the hydroxylated moieties in the
HIF-1α ODD. The α-domain of pVHL then recruits elongin B, elongin C, cullin-2, and ringbox 1 to form a complex which covalently links a chain of ubiquitin moieties to the ODD.
Polyubiquitinated HIF-1α docks with the 26S proteasomal complex which selectively
degrades ubiquitinated proteins [83 Maxwell 1999],[84 Ohh 2000]. The protein, SSAT2,
helps to stabilize the interaction of pVHL with elongin C thus facilitating ubiquitination
of HIF-1α. [85 Baek 2007]. Degradation by this pathway is rapid; cytoplasmic HIF-1α is
nearly undetectable under normoxic conditions, and the half-life of stabilized HIF-1α is
approximately 5 minutes upon cellular reoxygenation.
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The canonical pathway of HIF protein regulation, then, is as follows: In the
presence of oxygen, P4H2 hydroxylates HIF-1α, which can than be recognized by pVHL
and quickly degraded by the E3-ubiquitin ligase complex. In the absence of oxygen,
hydroxylation of HIF-1α does not occur and intracellular levels of the molecule increase.

1.2.5.2 Regulation of HIF-α Transcriptional Activity
The transcriptional activity of HIFs can also be regulated in an oxygen dependent
manner. HIF-α contains a nuclear localization signal in its CTAD, allowing stable HIF-α to
rapidly bind to nuclear pore proteins and translocate into the nucleus [86 Kallio 1998].
Once there, it is free to pair with HIF-β to form a functional HIF dimer. Ema et al. found
that the CTAD of HIF-α in the nucleus interacts with CBP/p300 to initiate transcription of
target genes [66 Ema 1999]. A key asparagine residue in this region (asparagine-803 in
HIF-1α and aspargine-851 in HIF-2α) can be hydroxylated by another hydroxylasedomain protein, termed factor inhibiting HIF (FIH), in the presence of oxygen [87 Lando
2002a].

The modification sterically inhibits HIF-α from interacting with CBP/p300,

necessary components of the transcription machinery [88 Lando 2002b]. P4H2 has a Km
for oxygen that is approximately 3 times greater than FIH; therefore, in moderately
reduced oxygen conditions in which HIF-α is beginning to be stabilized due to declining
P4H2 activity, FIH can still repress HIF activity by inhibiting DNA binding [89 Koivunen
2004].
As both major mechanisms for regulating HIF activity are hydroxylase-dependent,
it is clear that hydroxylases are central to cellular hypoxic responses. It is not surprising
then that, like HIF proteins themselves, the HIF regulatory hydroxylases also appear to
21

be highly conserved in vertebrates. Figure 1.3 summarizes how hydroxylase-domain
proteins act in regulating HIF.

Figure 1.3 Oxygen-dependent mechanisms of HIF regulation. In normoxia,
HIF-1α is constitutively expressed but protein levels are kept low by rapid
ubiquitination and proteosomal degradation. Activity of any nondegraded HIF-1α is suppressed by the failure of the p300 co-activator to
bind. In hypoxic conditions, oxygen dependency of both hydroxylases,
P4H2 and FIH, prevents HIF-1α modification, inhibiting degradation and
allowing for dimerization and binding of co-activators.

1.2.5.3 Additional Factors in HIF regulation
Though there seems to be limited redundancy in HIF regulation, several factors
other than PHDs can influence HIF activity in both oxygen-sensitive and oxygenindependent manners. Specifically, agents which have the ability to affect HIF mRNA
stability, PHD catalytic activity, pVHL affinity/polyubiquitination, and complexing of
HIF/BCP/p300/HRE can modulate HIF activity. Several miRNAs and mRNA-destabilizing
proteins have been shown to interfere with HIF-α mRNA stability [90 Taguchi 2008],[91
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Bruning 2011],[92 Chamboredon 2011]. It has also recently been shown that the
protein RACK-1 can bind to HIF-α and elongin C to recruit an E3 ubiquitin protein-ligase
complex in lieu of pVHL [93 Liu 2007]. This process is not dependent upon oxygen.
ROSs also appear to play a role in HIF regulation, presumably by oxidizing hydroxylasebound Fe2+ and abrogating its ability to serve as a cofactor in hydroxylating reactions [94
Pan 2007]. SIRT-3 was shown to help destabilize HIF-α by inhibiting ROS production [95
Finley 2001]. It is interesting to note that ROSs contribute to stabilizing HIF, as one of
the major behaviors regulated by HIF is oxygen conformance of the mitochondria.
Reducing oxidative phosphorylation in conditions of low oxygen presumably help limit
excessive ROS production which would lead to cell damage. It is not surprising to find,
then, that several metabolic intermediates of the citric acid cycle have also been
reported to inhibit hydroxylase activity, including citrate, isocitrate, malate,
oxaloacetate, pyruvate, succinate, and fumarate, [96 Kaelin 2008]. Luo et al. also found
that pyruvate kinase isoform M2 (PKM2), the enzyme that catalyses the final step in
glycolysis, can function as a coactivator of HIF-α [97 Luo 2011]. PKM2 can associate
directly with HIF-1/2α and p300 to enhance their binding to HREs. Additionally, the
mammalian target of rapamycin (mTOR) protein has been shown to enhance HIF activity,
and this enhancement could be inhibited by rapamycin [98 Semenza 2003],[99 Land
2007]. Finally, very recent studies have suggested that epigenetics are involved in the
regulation of HIF, with DNA and histone modifications altering accessibility and
transcribability of HIF target genes [100 Tanimoto 2010],[101 Mimura 2011],[102 Xu
2012],[103 Vanharanta 2013],[104 Nguyen 2012].
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1.2.6 Gradation of HIF Response
The sensitivity of P4H2 to changes in oxygen concentration also imparts a graded
responsiveness of HIF-1 to O2. Jiang et al. exposed HeLa cells to oxygen concentrations
ranging from 0% to 20% and measured levels of both HIF-1 subunit proteins as well as
HIF-1 DNA binding [105 Jiang 1996b]. As expected, the HIF-1α subunit was dramatically
responsive to oxygen concentration. Between 20% and 6% oxygen, HIF-1α levels and
DNA binding modestly increased as oxygen concentration decreased. However, below
6% oxygen both HIF-1α and HIF-1 DNA binding increased exponentially to reach
maximal values at 0.5% oxygen. Half-maximal responses were observed between 1.5
and 2% oxygen. Thus, the majority of HIF-1 activity takes place over a physiologically
relevant range of oxygen (0 - 5%), with the largest response occurring at physiologically
hypoxic levels (0.5 - 1.5%).
Bracken et al. tested the graded response of HIF-1 in a similar set of experiments
with a variety cell lines: HEK293T, HeLa, COS-1, HepG2, CACO-2, and PC12 cells [106
Bracken 2006]. In every case, they also found an exponential increase in HIF-1α protein
levels as oxygen was decreased from 5% to <1%. However, though HIF-1 activity, as
measured by reporter protein production, was also maximal below 1% oxygen, the
response did not always match HIF-1α protein levels. In addition to differences in
maximal reporter protein production levels between cells types, they noted two
categories of response. Some cells gradually increased reporter protein production as
oxygen decreased from 10% to <1%. Others required an oxygen concentration of <2%
before exhibiting a dramatic increase in reporter protein production, which much more
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closely coincides with changes in HIF-1α levels. This indicates that hypoxia is better
defined by cellular response than by absolute oxygen concentration.

1.2.7 Kinetics of HIF Response
The rate of HIF degradation/stabilization is also important to the responsiveness
of its activity. Traditional immunoprecipitation assays reveal a half-life for HIF-α of
approximately 5-8 minutes in normoxic conditions [65 Huang 1998],[107 Jaakkola
2001],[108 Jeong 2002]. Using a firefly luciferase reporter protein fused to the HIF-1α
gene, Moroz et al. reported a half-life of 4-6 minutes for the factor [109 Moroz 2009].
However, though HIF-α is very unstable in normoxia, HIF-α mRNA is constitutively
expressed and the protein is constantly produced. Additionally the Km of P4H2 for O2 is
just above the concentration of O2 in air. This high value ensures that even a small
decrease in oxygen is likely to have a significant effect on P4H2 activity [110 Hirsila
2003]. Thus HIF-1 can be both a highly-sensitive and rapidly-responsive initiator of
hypoxia response.
Wang and Semenza studied the kinetics of HIF-1α protein stabilization and DNA
binding in hepatoma cells exposed to 1% oxygen for 0-4 hours [111 Wang 1993b]. They
found that HIF-1 activity was first detectable within 15 minutes, with 8% maximal
activity at 30 minutes, 50% maximal activity between 1 and 2 hours, and maximal
activity at 4 hours. After rapid re-exposure to 20% oxygen, HIF-1 activity was reduced to
34% within 5 minutes and was eliminated by 15 minutes. The group also showed that
binding of stabilized HIF-1 to DNA occurred rapidly, with 77% binding within 1 minute

25

and 100% binding within 5 minutes. Likewise, DNA binding decay occurred with a t1/2 of
1 minute upon reoxygenation of the cells.
More recently, Jewell et al. used tonometers to rapidly equilibrate suspensions
of HeLaS3 cells to various oxygen conditions and study the time-course of HIF-1α
accumulation and degradation [112 Jewell 2001]. Presence and DNA binding of nuclear
HIF-1α was detected within 2 minutes of hypoxic exposure, with nuclear HIF-1α protein
levels reaching a maximal value by 1 hour. Within 2 minutes of reoxygenation, DNA
binding was reduced while nuclear HIF-1α protein levels were reduced within 4-8
minutes and undetectable by 32 minutes. These studies point to the capability of both
rapid onset and rapid cessation of hypoxic signaling by the HIF mechanism.

1.2.8 Transcriptional Targets of HIFs
The primary role of HIF-mediated transcriptional regulation is to promote cell
survival in acute hypoxia and cellular adaptation to prolonged hypoxia. As a rapid
response to hypoxia, HIF mediates global changes in metabolism in order to reduce
overall cellular ATP consumption. A traditional view of hypoxia held that lack of oxygen
would inhibit oxidative phosphorylation, limiting the production of ATP which would be
rapidly depleted if normal cell activities continued. As discussed, more detailed analyses
suggest that oxidative phosphorylation is not limited under normal physiological hypoxia,
but reduced oxygen concentrations affect its efficiency, resulting in higher levels of
premature electron loss from the ETC and greater ROS formation. In order to avoid
cellular ROS damage, HIF mediates the reduction of oxidative phosphorylation and the
activation of glycolytic metabolism. However, because glycolytic metabolism cannot
26

sustain the level of ATP production achieved by oxidative phosphorylation, HIF also
mediates cell-wide reduction of ATP-intensive activities to avoid depletion.
HIF additionally mediates cell behaviors which function to adapt a cell to
prolonged hypoxia or to remediate the hypoxic state.

For instance, HIF-induced

upregulation of EPO helps to increase the number of oxygen-carrying red blood cells in
the local vicinity. Such hypoxia-driven behavioral response are often observed during
embryonic development, where the local microenvironmental oxygen concentration
helps to inform cells about their relative bodily location and direct the behavioral
sequences that are required for normal organismal growth. It is not surprising, then, to
find that HIF functioning is mandatory to embryogenesis, with absence of HIF-1 function
being embryonic lethal [113 Maltepe, 1997],[114 Iyer 1998],[115 Ryan 1998]. Hif1a-/mice die at embryonic day 9 due to vascular and cardiac defect/deformity [114 Iyer
1998],[116 Melillo 1995].
Because of the number of processes that are linked to cell metabolism, and
therefore at least indirectly dependent upon oxygen, HIF has the potential for enormous
regulatory oversight in cells. To date, over 100 genes have been identified as direct
targets of HIF-1/2 [117 Loboda 2010]. These genes are involved in any number of cell
processes, including energy metabolism, transcriptional regulation, cell cycle and
growth, viability and apoptosis, transport, signaling, migration, matrix and barrier
function, paracrine activity, and differentiation [81 Schofield 2004],[118 Semenza
2000],[119 Ke 2006]. A list of well-known HIF targets are presented in Table 1.2.
Furthermore, because HIFs govern transcription of a large number of other transcription
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factors, the number of genes that are indirectly regulated by HIFs is much larger. In fact,
by some estimates, as many as 5% of the genes in the human genome are HIF-regulated
in hypoxic conditions [98 Semenza 2003]. In gene expression profiles performed in
arterial endothelial cells, Manalo et al. found that the largest group of genes upregulated by HIF-1 included transcription factors, with cytokines/growth factors,
receptors, and other signaling proteins also displaying significant upregulation [120
Manalo 2005]. Genes downregulated in hypoxia are generally involved in cell growth
and proliferation [120 Manalo 2005],[121 Goda 2003].

Using chromatin

immunoprecipitation and comparing results to genome-wide transcript profiling, other
groups likewise found a large number of genes to be up- and downregulated in hypoxia,
but reported that only upregulated genes appeared to contain an HRE sequence in the
promoter [122 Mole 2009],[123Schodel 2011]. This implies that direct transcriptional
regulation by HIF is accomplished almost entirely by gene upregulation (in fact over 20%
of genes upregulated in hypoxia were direct HIF targets [122 Mole 2009]), while down
regulation is accomplished indirectly. Indeed, of 191 genes downregulated in hypoxia in
five different cell types, Ortiz-Barahona et al. found none of them to be directly targeted
by HIF in all five cell types [124 Ortiz-Barahona 2010].
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Table 1.2 Direct transcriptional targets of HIF-1.
Function

Gene/Gene Product

Function

Gene/Gene Product

Glucose
Metabolism

Adenylate kinase 3
Aldolase A/C
Carbonic anhydrase-9
Enolase-1
Glucose transporter-1/3
Glyceraldehyde-3-phosphate
dehydrogenase
Hexokinase-1/2
Lactate dehydroxygenase A
6-Phosphofructo-2kinase/fructose-2,6bisphosphate-3
Phosphofructokinase L
Phosphoglycerate kinase-1
Pyruvate kinase M

Vasomotor
Regulation

Adrenomedullin
Atrial natriuretic peptide
Endothelial nitric-oxide
synthase
Endothelin-1
Heme oxygenase-1
Inducible nitric-oxide
synthase
Nitric oxide synthase 2
Tyrosine hydroxylase
α1B-adrenergic receptor

Erythropoiesis and
Iron Metabolism

Ceruloplasmin
Erythropoietin
Multidrug-resistance Pglycoprotein
Transferrin
Transferrin receptor

Matrix Function/
Metabolism

Collagen prolyl
hydroxylase
Ecto-5′-nucleotidase
Intestinal trefoil factor
Matrix
metalloproteinases
Procollagen prolyl
hydroxylase-α1

Cell Migration

Chemokine receptor
CXCR4
c-Met

Transcriptional
Regulation

DEC1
DEC2
ETS1
p35srj

Survival, Growth,
and Apoptosis

Angiogenesis

Bcl-2/adenovirus E1B 19kDinteracting protein-3
Calcitonin-receptor-like receptor
Endoglin
Insulin-like growth factor-2
Insulin-like growth-factor-binding
protein-1/3
Nip3-like protein X
p21
Transforming growth factor-α
Wilms’ tumour suppressor
α-Fetoprotein
Endothelial-gland-derived
vascular endothelial growth
factor
Leptin
Plasminogen-activator inhibitor-1
Transforming growth factor-β3
Vascular endothelial growth
factor A
Vascular-endothelial-growthfactor receptor-1

Compiled from references in 81 Schofield 2004, 118 Semenza 2000, and 119 Ke 2006.
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1.2.9 Cell Type Variation in HIF Responses
HIF-mediated responses to hypoxia also display heterogeneity between cell
types [125 Stroka 2001],[126 Chi 2006],[127 Gardener 2008],[128 Brachen 2006],[129
Lendahl 2009]. Benita et al. examined hypoxia-responsive genes in 7 different cell types
and found wide variability in HIF activity [130 Benita 2009]. Monocytes displayed 486
genes that were differentially expressed in hypoxia while HeLa cells displayed 2119 such
genes. Of these genes, 159 and 555, respectively, displayed an HRE sequence in the
promoter region. Furthermore, only 17 genes responded to hypoxia in all of the studied
cell types. The group concluded that a small subset of HIF direct-target genes, generally
involved in the shift from oxidative to glycolytic metabolism and cessation of cellular
growth/proliferation, represent the “core” HIF response to hypoxia.

Genes that

displayed variable responsiveness to hypoxia between cell types were less likely to
contain an HRE sequence, suggesting that cell-type variation in gene expression is
controlled indirectly by HIF.
Secondary factors that are involved in HIF indirectly-regulated pathways are
often affected by a cell’s phenotype and current physiologic context. This helps to
explain how cellular responses to hypoxia can vary despite similar levels of HIF mRNA
expression in most hypoxic cells. For instance, while most cells undergo inhibition of
proliferation in hypoxic conditions, vascular endothelial cells are often triggered to
divide and migrate under hypoxia as part of the angiogenic response.

Likewise,

Bcl2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) and p53 contribute to
HIF-regulated apoptotic cell death, while B-cell lymphoma 2 (Bcl-2) family proteins can
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promote HIF-regulated cell survival in hypoxia [127 Gardener 2008]. Because cellular
activity can impact the effect of HIF-signaling, it is reasonable to predict that cells whose
primary functions involve energy-intensive activities will be more negatively impacted
by hypoxia, while cells with low energy requirements should be tolerant of hypoxia.
Indeed, this appears to be the case: neurons, pancreatic β-cells, and cardiomyocytes are
all highly oxygen dependent, with their primary functions (de/re-polarization, muscle
contraction, and insulin secretion, respectively) being severely diminished in hypoxic
conditions. Alternatively, articular chondrocytes have very low metabolic requirements
and tolerate prolonged hypoxic exposure for the majority of their mature life cycle.
Of recent interest has been how the various HIF isoforms contribute to
differential hypoxic responses in different cell types. While HIF-1 is expressed in all
metazoan cells, HIF-2 is restricted to specific cell types in vertebrates [131 Semenza
2011a]. Furthermore while HIF-1 and HIF-2 exhibit some of the same target genes, they
can also mediate regulation of different cell functions without overlap. This means that
because both HIFs recognize the same HRE sequence in target genes, HRE and PHD
binding affinity for HIF-1 versus HIF-2 can influence which responsive cell behaviors are
elicited in hypoxia [132 Kenneth 2008]. While HIF-1 globally regulates genes involved in
glycolytic metabolism and complex patterns of genes affecting cell survival versus
apoptosis decisions, HIF-2 is only expressed in certain cells of the kidney, liver, pancreas,
lung, heart, intestine, and epithelium and does not contribute to affecting glycolysis
[117 Loboda 2010],[133 Hu 2003]. HIF-2 is prominently expressed in the vascular
endothelium during embryonic development and may contribute to maintenance of
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normal vascular architecture. It has also been shown to be the primary HIF isoform
mediating transcriptional regulation of octamer-binding transcription factor 4 (Oct4),
which is crucial to stem cell self-renewal, and transforming growth factor β (TGF-β) [134
Raval 2005],[135 Covello 2006]. HIF-3 acts as an antagonist to HIF-1 and HIF-2 by
forming a functionally inactive dimer with HIF-β [136 Makino 2001]. Elucidating the
different expression profiles, activities, and roles of the HIF isoforms in different
cells/tissues remains an active area of cellular research [128 Brachen 2006].

1.2.10 HIF: Implications for Identifying Hypoxia
Given the broad array of cellular behaviors that HIFs can mediate, and knowing
that physiological hypoxia is a normal and often required condition in organismal
growth, development, and activity, it is clear that identification of hypoxic status is of
import to biomedical research. However, identifying hypoxia, especially on the cellular
level, is tricky. Krohn et al. adroitly explain:

“Hypoxia is therefore a phenomenologic concept. There is no specific
value of O2Hb [oxyhemoglobin] concentration, % Hb saturation by
oximetry, or tissue partial pressure, PO2 measured with electrodes, that
results in a transition from normoxia to hypoxia… The biologic
consequences of hypoxia depend on duration and the needs of individual
cells…” [137 Krohn 2008]

Hypoxia, therefore, may be best defined in terms cell behavioral responses.

The

following section offers a discussion of current techniques for detecting hypoxia at the
tissue and cellular levels, highlighting advantages and disadvantages of each, and
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proposes that a fluorescent HIF reporter system is particularly well suited for identifying
hypoxia in 3D tissue cultures and engineered tissue constructs in vitro.

1.2.10.1 Current Methods for Detecting Hypoxia
Current strategies for identifying hypoxia are typically aimed at either tissue- or
cell-level detection. At the tissue level, evaluation usually consists of measuring or
analyzing some biomolecule present in the blood or interstitial fluid that is differentially
affected in hypoxic conditions. At the cell level, stains or markers are often used to
detect intracellular changes indicative of hypoxia. Hypoxia detection strategies can also
be categorized by whether they measure environmental conditions (oxygen
concentration) or biochemical conditions (behavioral changes).

1.2.10.1.1 Indirect Measures of Hypoxia
Many indirect techniques for imaging hypoxia at the tissue level have come from
cancer research, where hypoxia in tumors has been found to be associated with poor
outcomes. Magnetic resonance imaging (MRI) can be used to distinguish between
oxygenated hemoglobin and deoxyhemoglobin, giving an indication of local oxygen
availability in the vasculature of a given tissue [138 Kim 2005],[139 Leontiev 2007].
While this technique can be used to assess temporal changes in relative tissue
oxygenation, it is not capable of providing quantitative information. MRI can also be
used to measure increases in tissue lactate, which builds up as a result of increased
glycolytic metabolism. Both of these approaches measure downstream consequences
of hypoxia, which can exhibit some lag and also persist for a time even after normoxia
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has been restored. MRI can also be used to measure pO2 directly, using an oxygensensitive reporter perfluorocarbon injected into the site of interest [140 Mason
1993],[141 Zhao 2004]. This technique is dependent upon adequate perfluorocarbon
perfusion of the study tissue. However, for routine in vitro studies, use of MRI is
impractical. Furthermore, these techniques focus on identifying hypoxia on a tissuewide scale and may not have the resolution to identify hypoxia on the cellular level.
Various oxygen probes are also used to detect hypoxia. Microelectrodes can
precisely measure the local oxygen concentration down to a very small scale, and may
offer quantitative information about the oxygen conditions at a specific location, even at
the cellular level [142 Vaupel 1991],[143 Collingridge 1999],[144 Kim 2003],[145 Mason
2003]. However, they require O2 for detection, meaning that as oxygen concentrations
become very small, readings become less reliable. Fluorescent needle type oxygen
probes contain a fluorophore which is quenched in the presence of oxygen, eliminating
the variability of readings at low oxygen levels [146 Jorge 2006]. However, oxygen
probes of any kind provide only very local information about oxygen concentration and
require a large number of evaluations to obtain meaningful spatial information about
oxygen distribution. Furthermore, any such probe requires placement in the tissue,
leading to damage and inflammatory responses that can alter local tissue oxygen levels.
Nitroimidazoles represent a more direct method for identifying hypoxia.
Nitroimidazoles can act as oxygen mimetics, accepting terminal electrons from the ETC.
Their affinity for electrons is less than O2, so that under normal oxygen conditions only
low levels of nitroimidazoles are reduced. These molecules are only singly reduced and
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can still be easily oxidized by O2.

However, under hypoxic conditions, without

competition from oxygen, nitroimidazoles become doubly reduced, forming alkylating
agents that react indiscriminately with cellular macromolecules, thus trapping
nitroimidazole within the cell [137 Krohn 2008].

For tissue-wide analysis, the

nitroimidazole can be radiolabeled for positron emission tomography (PET) [147
Adamsen 2005]. Antibodies to the nitroimidazole, pimonidazole (commonly available as
Hypoxyprobe-1), have also been prepared.

This allows for immunohistochemical

staining and analysis of samples for the identification of hypoxia down to the cellular
level [148 Varia 1998],[149 Olive 2000],[150 Nordsmark 2003]. A primary disadvantage
of histological analyses is that they require the sacrifice of the tissue/construct under
study. Therefore, it is not possible to monitor the hypoxic status of the sample over
time or in response to changing conditions.
Another approach is to predict the occurrence of hypoxia by computational
modeling [151 Gross 2007],[152 Cheema 2008],[153 Buchwald 2009]. Models provide
the ability to draw predictive conclusions about expected oxygen concentrations and
gradients without the need for cell culture. However, while modeling is a powerful tool,
results are only as powerful as the assumptions on which the model is based, which in
turn are guided by current knowledge of the system being modeled. Therefore, an
incomplete understanding of cellular processes can lead to models which do not
accurately recapitulate observed phenomena.
The methods represent indirect approaches to detecting hypoxia. In these
techniques, indicators of hypoxia are evaluated but the immediate effector of response

35

to hypoxia, HIF, is not. Alternatively, direct HIF detection may be a better determinant
of hypoxia within a cell as it is the mediator which transitions a cell’s status from
“normal” to “hypoxic”.

1.2.10.1.2 Direct Measures of Hypoxia: HIF Detection
Direct detection of HIF is perhaps a more telling indicator of whether or not a
cell is experiencing hypoxic stress than measurements of oxygen or detection of
metabolites involved in secondary hypoxia responses. HIF-1 stability is highly sensitive
to oxygen concentration with a graded and rapid response to hypoxia.

Thus,

intracellular levels of HIF-1 both directly correspond to a cell’s immediate state of
oxygenation and are predictive of imminent biochemical cellular responses that occur as
HIF activity affects transcription. Real-time polymerase chain reaction (RT-PCR) can be
performed to quantify changes in HIF-α mRNA levels; however, as HIF-α is constitutively
expressed in most cells, this is not a good indication of transition of a cell to a hypoxic
state. Alternatively, the HIF-α protein itself can be identified. This is commonly done by
immunohistochemical/immunofluorescent staining, which can indicate HIF localization
in a tissue, or by Western blotting which allows for quantification by densiometry.
These methods directly measure a cell’s hypoxic status. However, they do suffer from a
number of drawbacks. First, the short half-life of HIF-α makes accurate capture and
determination of protein levels difficult. Secondly, basal and elevated HIF-α levels can
vary among cell types, meaning that specific concentrations of HIF-α do not always
correspond directly to a consistent level of transcriptional changes in a cell. Most
importantly, however, is that both immunostaining and Western blotting protocols
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require the sacrifice of the tissue of interest. This means that repeated analysis of
hypoxic status within the same sample cannot be performed. Thus by these methods, it
is difficult to develop a temporal profile of the hypoxic response within a cell.
An alternative approach to HIF protein detection is the use of a reporter system.
Several groups have detailed the use of an engineered vector containing repeats of the
HRE enhancer and a minimal promoter to allow for hypoxia-induced expression of a
fused gene. Given the appropriate reporter protein, this approach conveniently allows
for the kinetics and magnitude of HIF-mediated effects on transcription to be observed.
Furthermore, if the reporter protein is non-toxic to the cell and is easily detected,
repeated observations of the same sample can be made.
The majority HIF reporter vectors detailed in the literature have been
constructed as potential targeted gene-therapies for cancer treatment or diagnostic
tools for the identification of hypoxia in tumors. Shibata et al. prepared a vector
containing five HRE repeats from the human VEGF gene coupled to a minimal
cytomegaloviral (CMV) promoter with luciferase as a reporter gene [154 Shibata 2000].
They reported a 500-fold increase in luciferase expression in response to hypoxia in
transfected cells. This type of vector was suggested as a means to selectively express a
therapeutic agent (in lieu of the luciferase reporter gene) in tumors which are generally
hypoxic compared to normal tissues [154 Shibata 2000],[155 Payen 2001]. Indeed, a
similar vector containing a suicide gene (herpes simplex virus thymidine kinase) under
HRE control was used to induce tumor regression in mice [156 Koshikawa 2000].
Similarly, Harada et al. used a HRE-luciferase reporter system to observe changes in the
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number of hypoxic cells within a tumor to evaluate the effectiveness of cancer drugs
[157 Harada 2005].
The recent characterization and marketing of a number of genes whose
products are stable fluorescent proteins has also allowed for the construction of
imagable hypoxia reporter systems. Vordermark et al. reported the suitability of green
fluorescent protein (GFP) as a reporter gene product for identifying HIF activity at
oxygen concentrations as low as 0.02% [158 Vordermark 2001].

Serganova et al.

transfected C6 glioma cells with an HRE-GFP reporter vector and observed green
fluorescence, indicating HIF-mediated transcriptional activity, in tumor masses
comprised of the cells [159 Serganova 2004]. They noted the particular usefulness of
this approach for determining dynamics and spatial heterogeneity of HIF-1-specific
transcriptional activity [159 Serganova 2004].
A fluorescent reporter of HIF activity appears to be a relevant and useful tool for
determining whether or not a cell is hypoxic and investigating different
microenvironmental conditions that can result in HIF-induced changes in cell behavior.
Such a system identifies cellular hypoxia in terms of cell behavior and offers a good
estimate of the expression of other direct HIF targets. The method also avoids a
number of the problems inherent in other hypoxia detection techniques, such as the
need to sacrifice the study sample. However, very little use of such a system outside of
tumor hypoxia has been reported. As discussed, low oxygen conditions can be common
in the human body and can be necessary to drive normal and appropriate biological
processes. As researchers make increasing efforts to simulate in vivo conditions in their
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in vitro studies, there is an apparent need to understand how environmental signals, like
oxygen tension, in a cell’s physiological environment contribute to affecting its function.
Use of a fluorescent reporter system to identify HIF activity and correlate it to other
relevant changes in cell behavior should begin to fulfill this need.

1.3 Regulating Hypoxia to Affect Cell Behaviors in Transplantation Therapies
The loss or failure of tissues and organs due to damage and disease is one of the
most prevalant and expensive problems encountered in medicine today [160 Laschke
2006]. Since it was officially defined by the National Science foundation in 1987, the
field of tissue engineering has offered the promise of addressing this issue through
development of functional replacement tissues that are transplanted into the recipient
[161 Langer 1993]. With the subsequent discovery and utilization of embryonic and
adult stem cells, tissue engineering has slowly become encompassed under the
umbrella of “regenerative medicine”, which, as defined by Mason and Dunnill,
“…replaces or regenerates human cells, tissues or organs to restore or establish normal
function” [162 Mason 2008].

By this definition, any cell-transplantation therapy

qualifies as regenerative medicine. Regenerative medicine combines the use of cells,
materials, and bio-physical/chemical stimuli in a rational effort to produce functional
tissues that are closely analogous to native tissues for the treatment of defects or
disease. A key feature of regenerative medicine is the harnessing of innate properties
and capabilities of cells that are difficult, if not impossible, to reproduce artificially. The
cellular genome contains all of the inherent instructions required to run the myriad
biological processes that together result in a living organism. Through evolution, these
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have developed into a highly regulated and enormously complicated pattern of
conserved and emergent cell behaviors that allow for survival and reciprocal interaction
with the world.

Tissue engineers, then, have the difficult task of applying, in an

intelligent manner, what information has been learned about these preprogrammed cell
functions in order to drive desired cell behaviors while restricting undesired ones in an
effort to develop therapies for tissue restoration.
It has become increasingly noted that for cell transplantation and tissue
engineering endeavors to succeed, the in vitro conditions in which tissue
growth/fabrication takes place will need to closely mimic the native physiological
environment. Differences between the conditions that cells encounter in culture and in
the body can lead to discrepancies between in vitro and in vivo results. One of the most
non-physiological conditions encountered by cells in routine cell culture is elevated
exposure to oxygen. In atmospheric culture conditions, cells are exposed to nearly 21%
O2, whereas oxygenation of a typical tissue in the body is much lower. Therefore,
investigators using standard culture conditions may not observe the same responses
from cells as might typically be seen in vivo.

As more research is performed at

physionormal oxygen concentrations, it will be important to monitor the hypoxic status
of cells in culture and observe the effects of reduced oxygen on cell behavior.
Furthermore, tissue engineering is often concerned with the production of 3D tissues,
which differ widely from the monolayers typical of standard culture. Because oxygen
delivery occurs by diffusion from the media in vitro, oxygen gradients can easily form in
3D tissues, thus exposing cells to heterogeneous oxygen conditions. Because of this,
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oxygen tension in many tissue engineered constructs may exert a significant, and
potentially more complicated, effect on cell behavior than is typically considered.
A fluorescent hypoxia reporter system, described in the present work, provides a
means for evaluating hypoxia and its effects in different cell systems. Though its role in
signaling has become much better understood, “hypoxia” is still often viewed with a
negative connotation, as it can lead to aberrant cell behavior and cell death. However,
many beneficial behaviors, such as vascularization and wound healing, can also be
triggered by hypoxia. Thus, hypoxia’s role in cell transplantation and tissue engineering
is phenomenological and context dependent. In the present work, it is hypothesized
that for different 3D tissue systems, tissue dimensions and external oxygen
concentration (both controllable culture parameters in vitro) contribute to the hypoxic
status experienced by cells within the culture, and can work to promote desirable,
hypoxia-induced behaviors or, alternatively, to inhibit cell function (Figure 1.4). This
dual nature of hypoxia in cell-based, tissue engineering therapies, as well as the
versatility of a fluorescent HIF reporter for use in its study, is highlighted in two systems
which were the subject of the present work: islet-like β-cell clusters, and ADSC
spheroids. In β-cell clusters, beneficial cell behavior is achieved by avoiding hypoxia,
while in ADSC spheroids, hypoxia promotes the desired behavior. The importance of
these systems as transplantation therapies as well as the role of hypoxia in each is
discussed in the following sections.
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Figure 1.4 Schematic of development of hypoxia in 3D
cultures. The extent of hypoxia within a cell aggregate
should be affected by aggregate size and external oxygen
concentration. To achieve the desired cell behavior, it may
be possible to vary these parameters to optimize hypoxic
status throughout the aggregate.

1.3.1 Encapsulated β-cells as a Treatment for Type I Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is a chronic inflammatory disease of the
pancreas resulting in the body’s inability to produce insulin. β-cells, the cells responsible
for insulin production and secretion, reside within specialized tissue clusters called the
islets of Langerhans found within the pancreas. In T1DM, the β-cells are destroyed,
presumably through a dysfunctional autoimmune process.

Without the insulin

produced by β-cells, the body tissues are unable to take in and utilize glucose, the
primary energy product of metabolism and the body’s main energy source. If untreated,
T1DM is fatal.
There are currently several treatment options for T1DM, offering the potential to
improve patient prognosis considerably. Exogenous insulin administration via injection
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is the most prevalent such option. By constantly monitoring blood glucose levels and
administering insulin when needed, diabetic patient quality of life and life expectancy
can be much improved. However, besides the discomfort of repeated blood drawl and
hypodermic injection, this method also inadequately replicates what the body does
naturally. In the body, islets are well perfused with blood and β-cells can continually
monitor blood glucose levels and respond by secreting the appropriate amount of
insulin. This continual monitor/secrete system is called responsive release, and it
ensures that at any given moment the amount of insulin and glucose in the blood are
appropriately balanced to achieve the correct physiological function.
supplementation of insulin, however, occurs in doses.

Exogenous

Doses are administered

periodically in amounts estimated to adequately process the glucose load of a meal over
a given time period. Such periodic administration means that insulin concentration is
not necessarily matched to glucose concentration at all times. Thus, exogenous insulin
supplementation often fails to prevent the chronic, systemic complications of T1DM,
such as retinopathy, glaucoma, neuropathy, and hypertension, over time.
In the normal physiological state, the body naturally secretes insulin in a
responsive manner dependent upon blood glucose concentration at a given moment. It
stands to reason, then, that an ideal method for treating T1DM would do the same.
Because β-cells are specifically specialized to perform this task, transplantation of
functional pancreatic tissue to replace compromised islets offers an appealing
treatment approach. Transplantation was first attempted as a treatment for severe
T1DM in 1966, with allotransplantation of a pancreas, duodenum, and kidney
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concurrently [163 Kelly 1967]. This and other subsequent early attempts offered poor
outcomes due to complications from the invasive surgery and the requirement of
immunosuppressive drugs to prevent organ rejection. Later transplantation attempts
made use of the fact that islets represent only a small percentage of the total pancreatic
mass but are sufficient for remediating T1DM. Islets were isolated and purified from
donor pancreata and transplanted into recipients, greatly reducing surgical invasiveness
but still requiring a life-long immunosuppressant regimen to prevent rejection. Besides
issues with long-term immunosuppressant drug use, transplantation procedures also
suffer from donor limitations. The islets from as many as three donors are required to
satisfy the needs of single recipient. Thus, although positive outcomes have been
achieved by islet transplantation, methods to improve the procedure and overcome
limited tissue supply continue to be explored.
Encapsulation has been considered as means of overcoming the main
shortcomings of islet transplantation. Encapsulation separates the transplanted tissues
from the cells of the immune system and offers two benefits. First, possibility of
immune rejection is greatly reduced so that immunosuppressive drugs are not required.
Secondly, the avoidance of an immune response makes utilization of xenotypic tissue
sources a potential way to overcome limited donor supply. Lim and Sun first evaluated
the potential of this technique by encapsulating rat islets in semipermeable, cross-linked
alginate [164 Lim 1980]. They then examined viability and function of the islets in vitro
and in chemically induced diabetic rats. They found that encapsulated islets exhibited
glucose-stimulated insulin secretion (GSIS) similar to unencapsulated islets and could
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restore normoglycemia in the mice for at least 20 days, compared to six day survival of
mice

receiving

unencapsulated

islets.

More

recent

trials

have

shown

xenotransplantation proof of concept, with alginate-encapsulated pig islets functioning
to remediate hyperglycemia in diabetic monkeys [165 Dufrane 2006a] and dogs [166
Abalovich 2009] for several months without immune rejection.

Elliott et al. even

reported viability of alginate-encapsulated pig islets 9.5 years after transplantation into
a human (function was lost after 14 months) [167 Elliott 2007], thought a second group
was unable to duplicate the result [168 Tuch 2009]. However, limited duration of
viability/function of encapsulated islets has largely restricted the overall success of
transplantation therapies. Capsule material and nutrient delivery (especially oxygen)
are the two major parameters that appear to most affect encapsulated islet
performance.

1.3.1.1 Poly(Ethylene Glycol) as a Favorable Material for β-Cell Encapsulation
A majority of current encapsulation trials utilize hydrogels as the semipermeable
matrix which separates β-cells from immune cells. Hydrogels are appealing for their
ability to hold many times their volume in water, which provides a large aqueous
environment for the encapsulated cells. Though alginate-based gels are traditionally the
most utilized, poly(ethylene glycol) (PEG) hydrogels represent a promising alternative. A
shortcoming of alginates has been their propensity to become fibrotically overgrown if
not adequately purified [169 Langlois 2009] and their batch-to-batch variability making
comparisons between studies difficult. Recent direct comparisons have shown that, in
these two respects, PEG yields superior performance [170 Liu 2010]. In addition to
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being highly biocompatible, PEG is also easily functionalized and non-degrading when
covalently crosslinked. PEG hydrogels have already been shown to support a number of
cell types including chondrocytes [171 Bryant 2002],[172 Rice 2004], osteoblasts [173
Burdick 2002], valvular interstitial cells [174 Benton 2009], and mesenchymal stem cells
[175 Nuttelman, 2004]. PEG network permeability, a function of mesh size, is also easily
manipulated by varying macromer concentration and size in the photoactive solution
[176 Cruise 1998]. Lin-Gibson et al. provided a method for photopolymerizing PEG
dimethacrylates (PEGDM) that had been prepared by microwave methacrylation of PEG
[177 Lin-Gibson 2004]. Using this method, Weber et al. showed that polymer mesh size
was easily controlled by appropriate selection of initial macromer size [178 Weber 2008]
and that such hydrogels were suitable for sustaining β-cells [179 Weber 2006]. Bryant
et al. showed that neither the photoinitiator nor time of UV exposure used in the
photopolymerization process was toxic to the cells [180 Bryant 2000].

1.3.1.2 Hypoxia in Islet Encapsulation
Loss of function and/or viability is often observed in a significant percentage of
cells following tissue isolation and encapsulation procedures. This has been especially
noted of islets of Langerhans, transplanted as a treatment for T1DM [181 De Vos
1997],[182 Suzuki 1998],[183 De Vos 1999]. While a variety of factors have been
investigated, hypoxia has increasingly been implicated as the primary cause for this
observed device failure, with insulin secretion by the pancreatic β-cells being
particularly sensitive to changes in oxygen concentration [184 Dionne 1989],[185
Dionne 1993],[186 de Groot 2003]. Low oxygen tension in explanted islets can be
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directly attributed to their removal from the rich vasculature of the pancreas.
Encapsulation exacerbates this problem in two ways: 1) by prohibiting islet
revascularization and 2) by adding an additional barrier to oxygen transport. Outcomes
in unencapsulated islet transplants have shown that diffusion of oxygen and nutrients to
islets in well-perfused sites of the body prior to revascularization can be sufficient to
maintain viability and function [187 Shapiro 2000],[188 Shapiro 2006]. A capsule,
however, may hinder diffusion of oxygen to encapsulated tissues because of
permeability limitations and increased diffusional distance [189 Schrezenmeir 1994].
However, besides material and geometric considerations of capsule design, a variety of
factors such as islet size [190 Lehmann 2007],[191 Cavallari 2007], rate of oxygen
consumption [192 Sweet 2002],[193 Wang 2005], and site of implantation [194 Dufrane
2006b] all play a part in determining how much oxygen may be available to any
particular cell.
Oxygen insufficiency is known to inhibit β-cell function by decoupling glucose
sensing from insulin exocytosis [195 Zehetner 2008],[196 Cantley 2009],[197 Puri 2009].
Studies characterizing how size, encapsulation material, and external oxygen conditions
affect the hypoxic status of islets as well as how techniques such as re-aggregation and
hypoxic preconditioning contribute to hypoxic tolerance (if at all) are obviously
important to optimizing implant function. However, direct characterization of hypoxia,
in terms of HIF activity, in β-cells is scarcely reported. In the present work, use of a
fluorescent HIF reporter was shown to facilitate such investigations, allowing for the
determination of temporal and spatial profiles of hypoxia in 3D, islet-like clusters and
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observation of how cluster size and external oxygen concentration contribute to
hypoxia-mediated effects on cell function.

1.3.2 ADSC Spheroids as a Cell-Based Method to Drive Angiogenesis
Despite its promise, tissue engineering has offered relatively few clinical
successes to date [198 Griffith 2002],[199 Ikada 2006].

Lack of vascularity has

consistently been cited as the largest obstacle to the development of clinically relevant
engineered tissues over the past several years [160 Laschke 2006],[200 Rauwkema
2008],[201 Lovett 2009],[202 Santos 2010],[203 Novosel 2011],[204 Horch 2012],[205
Laschke 2012].

Most cells in the body reside within 100-200μm of a blood vessel, a

distance which corresponds closely the theoretical limit of oxygen diffusion in a tissue
[206 Folkman 1973],[207 Colton 1995]. For engineered tissues, which are avascular, this
diffusional restraint limits the size of tissues that can be effectively transplanted.
Following transplantation, local inflammation and healing processes at the implant site
resulting from the surgical procedure can help to induce infiltration of host vessels into
the implant. However, the rate of vessel progression is slow and interior cells of the
implant often do not survive long enough to be vascularized. Several strategies for
enhancing vascularization of engineered tissues have been described, including
administration of pro-angiogenic growth factors, cell co-culture, and pre-vascularization.
These strategies either attempt to promote angiogenesis, the sprouting of vascular
branches from existing vasculature, or vasculogenesis, the de novo formation of
microvessel networks from disorganized precursor cells.
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Growth factors are known to be potent mediators of angiogenesis and
vasculogenesis in vivo. VEGF is the most powerful stimulator of angiogenesis, often
working in concert with basic fibroblast growth factor (bFGF) [208 Carmeliet 2011].
When triggered by these growth factors, endothelial cells in existing vessel walls secrete
matrix metalloproteinases (MMPs), branch off from the vessel, and begin to migrate in
the direction of the growth factor source.

Endothelial cells directly behind these

migrating cells begin to proliferate rapidly, extending a new capillary sprout toward the
tissue of need.

Subsequent vessel maturation is important to reducing capillary

leakiness and preventing vessel regression. Platelet-derived growth factor (PDGF), TGFβ, and angiopoietin 1 (Ang-1) are involved in vessel stabilization and maturation by
reducing MMP secretion, stimulating matrix production, and recruiting supporting cells
such as smooth muscle cells and pericytes [200 Raukema 2008],[209 Carmeliet
2000],[210 Hirschi 2002].
In regenerative medicine applications, administration of angiogenic factors can
help to stimulate blood vessel growth and promote more rapid vascularization of tissue
implants.

For this purpose, recombinant VEGF is often applied.

VEGF can be

administered by direction injection; however, high dose requirements due to VEGF
instability and negative systemic side-effects, including ectopic blood vessel
development and excessive capillary leak, make this delivery technique unfavorable
[160 Laschke 2006]. An alternative strategy has been to localize VEGF to the implant
site by controlling its release from the implant itself, often a biomaterial scaffold that
serves as the matrix component of an engineered tissue. Many demonstrations of
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material-based constructs for VEGF delivery are reported in the literature, displaying a
wide variety of release profiles and mechanisms [211 Zisch 2003],[212 Sokolsky-Papkov
2007],[213 Übersax 2009],[214 Fu 2010]. However, material-based delivery systems do
face a number of hurdles. First, they require both a prior knowledge of the appropriate
delivery dosage/duration and the ability to achieve this release profile from a material
construct. Also, the maximal cumulative dose is predefined by the loading process
during fabrication and cannot be augmented after implantation. Furthermore, few
systems are capable of responding to cellular and other microenvironmental cues that
would modulate delivery to match physiological need.

Finally, the process of

angiogenesis is driven by concurrent action of multiple factors each displaying different
availability profiles which change over time; however, the appropriate relative profiles
of many growth factors are not fully characterized in many cases, and most materialbased growth factor delivery systems have difficulty incorporating and delivering
multiple factors differentially.

1.3.2.1 Cell-Based Delivery for Therapeutic Angiogenesis in Tissue Engineering
A more recent technique has been to use cells as a growth factor source, an
approach termed cell-based delivery. In cell-based delivery, a particular cell type is
chosen for incorporation into the engineered tissue to promote tissue angiogenesis,
either natively or by some inducing stimulus.

Cell-based delivery techniques are

attractive, as researchers are able to take advantage of natural biological mechanisms
that cells already possess. This approach offers three key benefits [200 Rauwkema
2008]. First, unlike most biomaterials, cells can participate in innate biological signaling
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processes that regulate angiogenic factor secretion to maintain factor concentrations in
the physiological range and adapt them to meet the requirements of different stages of
vessel formation. Secondly, growth factors secreted from cells often interact with the
extracellular matrix to form three dimensional microgradients which contribute to
directing capillary arrangement [215 Helm 2005]. Finally, cells may have the capability
to produce and secrete a variety of different angiogenic factors, in physiological profiles,
that act together to direct several stages of vessel migration, stabilization, and
maturation [205 Laschke 2012].
For cell-based delivery to be effective, a cell source must be chosen that is
capable of producing the factors of interest and providing the appropriate signals within
the implant microenvironment. The recently-characterized ADSCs represent a very
promising cell population for the promotion of angiogenesis. ADSCs are readily isolated
from lipoaspirates which can be collected through a minimally invasive procedure. The
stem cell yield from adipose tissue is large, approximately 500 times greater than from
bone marrow, where similar stromal cell populations were first identified [216 Mizuno
2009]. Ease of culture and rapid expansion make ADSCs ideal for autologous use.
ADSCs have also been shown to be capable of secreting a number of factors of relevance
to angiogenesis in regenerative medicine, including VEGF; bFGF; hepatocyte growth
factor (HGF); basic nerve growth factor (bNGF); angiogenin; Ang-1; insulin-like growth
factor 1 (IGF-1); interleukins (IL)-6, -7, -8, -11, and -17; monocyte chemoattractant
protein (MCP)-1 and -2; granulocyte/monocyte-, granulocyte-, and macrophage colony
stimulating factors (CSF); tumor necrosis factor α (TNF-α), and stromal cell-derived
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factor 1 (SDF-1) [217 Kilroy 2007],[218 Hong 2010],[219 Rasmussen 2011]. Furthermore,
ADSCs have shown the potential to differentiate into a variety of mature lineages of
mesodermal and non-mesodermal origin, including adipogenic, chondrogenic,
osteogenic, skeletal muscle, smooth muscle, cardiac muscle, epithelial, hepatocytic,
pancreatic, and hematopoietic support cells [216 Mizuno 2009]. Of particular relevance
are studies indicating that ADSCs can differentiate directly into endothelial precursor
and endothelial cells [220 Planat-Benard 2004],[221 Miranville 2004],[222 Cao
2005],[223 Colazzo 2010],[224 Keerl 2010],[225 Shi 2012].
In recent years, ADSCs have been shown to contribute to improved tissue repair
in dermal wounds [226 Kim, W.S. 2007],[227 Lu 2008],[228 Kim 2009],[229 Nambu
2009], mouse ischemic hindlimbs [221 Miranville 2004],[222 Cao 2005],[230Nakagami
2005],[231 Moon 2006],[232 Kim, Y. 2007], and myocardial infarcts [233 Miyahara
2006],[234 Valina 2007],[235 Cai 2009],[236 Schenke-Layland 2009],[237 Wang 2009].
Usually, the cells are directly injected into the deficient tissue as a dispersion, or a
seeded into a tissue scaffold for implantation. The restorative effects of ADSCs have
mostly been attributed to their enhancement of angiogenesis, which appears to be
accomplished through one or more of the following mechanisms.

First, current

evidence supports a primary paracrine activity of ADSCs, with secretion of proangiogenic and anti-apoptotic growth factors contributing to enhanced tissue survival
and increased capillary density. (VEGF and IGF-1, for instance, have been shown to
function in both roles [219 Rasmussen 2011].) ADSCs also secrete factors which can
recruit circulating stem and endothelial precursor cells, as well as various support cells
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such as fibroblasts and pericytes [238 Takahashi 1999],[239 Crosby 2000],[240 Ceradini
2005],[241 Nakao 2010]. In particular, SDF-1, appears to function in stem cell homing
[242 Askari 2003],[243 Ceradini 2004]. Finally, as mentioned, ADSCs can differentiate
into endothelial cells to directly integrate into developing vasculature. ADSCs also share
many common characteristics with pericytes, cells which support the vascular
endothelium and have been shown to contribute to superior angiogenesis and vessel
stabilization when co-cultured with endothelial cells [244 Traktuev 2008],[245 Traktuev
2009]. Taken together, these properties suggest that ADSCs are capable of modulating
the stem cell niche to create a local microenvironment that is highly primed to promote
angiogenesis [246 Gimble 2007].

1.3.2.2 Hypoxia and the Angiogenic Potential of ADSCs
In order to fully take advantage of the angiogenic potential of ADSCs for
regenerative medicine, researchers will need to develop techniques to control and
possibly amplify their pro-angiogenic behaviors. To this end, a better understanding of
the stimuli that encourage these behaviors will be advantageous. In the body, ADSCs
reside in a perivasacular niche with oxygen concentrations ranging from 2-8% O2, an
environment that has been described as locally hypoxic [247 Matsumoto 2005],[248
Pasarica 2009],[249 Mohyeldin 2010]. This concentration encompasses the range over
which HIFs are exponentially stabilized, suggesting that HIF activity plays an important
part in regulating typical ADSC functions. Indeed, hypoxia appears to be one of the
primary motivating factors promoting ADSC paracrine activity and affecting differential
potential. Hypoxic culture of ADSCs has been reported to upregulate expression of
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VEGF, bFGF, IGF-1, and HGF in vitro [219 Rasmussen 2011],[250 Rehman 2004],[251
Rosová 2008], [252 Lee 2009],[253 Liu 2013]. In particular, the VEGF gene is known to
contain HRE repeats in its promoter region, making it a direct target of HIF-1 [254 Levy
1995],[255 Liu 1995],[256 Forsythe 1996]. In animal studies, hypoxic preconditioning of
ADSCs resulted in superior survival, healing, and vascularity of ischemic skin flaps and
myocardial infarcts in mice [257 Tang 2009],[258 Yue 2013]. Hypoxia has also been
suggested to contribute to an increase in stem cell survival and to the secretion of prosurvival factors from stem cells [259 Chacko 2010]. However, despite the fact that the
potent angiogenic properties of ADSCs are largely regulated by hypoxia over
physionormal oxygen tensions, relatively little work has focused on developing a better
understanding of how cellular hypoxia in encountered by ADSC cultures. Furthermore,
Abdollahi et al. have recently concluded that “…further study is needed to optimize the
use of hypoxia as a stimulus for various stem cell functions, including its potential role in
therapeutic angiogenesis” [260 Abdollahi 2011].
Realization that oxygen is one of the key regulators of stem cell function has a
profound significance on how current cell-based and tissue engineering applications
using ADSCs can be further improved [261 Zachar 2011].

While upregulation of

angiogenic growth factors by genetic engineering has been shown to enhance the
therapeutic outcomes with stem cells [262 Geiger 2007], hypoxia can be used to a
similar effect while eliciting a more global and complex cell response and avoiding
potential concerns such as oncogene formation [263 Baraniak 2010]. As discussed
previously, oxygen diffusion in a 3D tissue is known to affect oxygen tension. Therefore,
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in the present work, it is suggested that 3D and hypoxic culture can be used to illicit
upregulation of angiogenic behavior in ADSCs. In addition to the potential paracrine
effects, 3D culture has been shown to enhance survival of cells within a spheroid
through contact-dependent signaling and upregulation of pro-survival factors [264
Shweiki 1995],[265 Bates 200],[266 Gaedtke 2007],[267 Bhang 2012a]. Furthermore, 3D
culturing may serve to precondition the cells for hypoxic conditions encountered at the
ischemic implant site [268 Saleh 2011],[269 Baraniak 2012]. Application of a fluorescent
HIF reporter system allows for a unique characterization of hypoxia within 3D ADSC
cultures which should serve as a supplement to the few investigations of hypoxia in
ADSC spheroids. Furthermore, it is hypothesized that spheroid size and external oxygen
concentration can be adjusted to affect hypoxic status of cells throughout a culture, and
thus control the output of angiogenic factors. This hypothesis is investigated in the
current work. Using culture size to control hypoxia for tissue engineering has not been
previously reported in the literature and has implications for optimizing tissue designs
for angiogenic cell-therapies in regenerative medicine.

55

Chapter 2
Correlating Hypoxia with Insulin Secretion Using a Fluorescent Hypoxia
Detection System1

______________________________
M.L. Skiles, R. Fancy, P. Topiwala, S. Sahai, J.O. Blanchette. Correlating hypoxia with
insulin secretion using a fluorescent hypoxia detection system. J Biomed Mater Res B
Appl Biomater 2011, 97(1);148-55. (published) [270 Skiles 2011a]

1
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2.1 Abstract
A common obstacle to the survival of encapsulated tissue is oxygen insufficiency.
This appears particularly true of encapsulated pancreatic β-cells. Our work investigates
a fluorescent hypoxia detection system for early recognition of hypoxic stress in
encapsulated pancreatic tissue. Murine insulinoma (MIN6) cells were engineered to
produce a red fluorescent protein under the control of hypoxia-inducible-factor-1.
Aggregates of these cells were encapsulated in poly(ethylene glycol) hydrogels at
densities of 200,000, 600,000, and 1 million cells per capsule then incubated in either a
1% or 20% oxygen environment. Cell function was evaluated by daily measurement of
glucose-stimulated insulin secretion. Encapsulated cells were also fluorescently imaged
periodically over 72 hours for expression of the marker signal. Results indicate that
oxygen insufficiency severely impacts insulin release from MIN6 cells, and that large
aggregates are especially vulnerable to oxygen limitations. Our marker was found to be
successfully indicative of hypoxia and could be used as a predictor of subsequent insulin
release. Further work will be required to fully characterize signal dynamics and to
evaluate in vivo efficacy. The method presented here represents a unique and valuable
approach to detecting hypoxic stress in living tissues which may prove useful to a variety
of fields of biological research.

2.2 Introduction
Loss of function and/or viability is often observed in a significant percentage of
cells following tissue isolation and encapsulation procedures. This has been especially
noted of islets of Langerhans, transplanted as a treatment for T1DM [181 de Vos
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1997],[182 Suzuki 1998],[183 de Vos 1999]. While a variety of factors have been
investigated, hypoxia has increasingly been implicated as the primary cause for this
observed device failure, with insulin secretion by the pancreatic β-cells being
particularly sensitive to changes in oxygen concentration [184 Dionne 1989], [185
Dionne 1993],[186 de Groot 2003].
Low oxygen tension in explanted islets can be directly attributed to their removal
from the rich vasculature of the pancreas. Encapsulation exacerbates this problem in
two ways: 1) by prohibiting islet revascularization and 2) by adding an additional barrier
to oxygen transport. Outcomes in unencapsulated islet transplants have shown that
diffusion of oxygen and nutrients to islets in well perfused sites of the body prior to
revascularization can be sufficient to maintain viability and function [187 Shapiro
2000],[188 Shapiro 2006]. A capsule, however, may hinder diffusion of oxygen to
encapsulated tissues by permeability limitations and an increased diffusional distance
[189 Schrezenmeir 1994].

For many commonly used materials, oxygen can easily

permeate and diffuse within the capsule. Weber, et al. [178 Weber 2009], for instance,
have shown that the diffusion coefficients of small molecules within a poly(ethylene
glycol) (PEG) hydrogel polymerized from 10 kDa macromers approach their values for
diffusion in water. This implies that in terms of oxygenation, combined effects of
capsule geometry and material may largely influence device success. However, beyond
material and geometric considerations, a variety of factors such as islet size [190
Lehmann 2007],[191 Cavallari 2007], rate of oxygen consumption [192 Sweet 2002],[193
Wang 2005], and site of implantation [194 Dufrane 2006b] all play a part in determining
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how much oxygen may be available to any particular cell. As such, a method for quickly
detecting hypoxia in individual living cells would provide obvious benefits to the field of
cell encapsulation.
Our work reports the development of such a detection system.

HIF-1, a

heteromeric dimer, has previously been identified as central to cellular hypoxia
response [271 Semenza 2001]. In particular, presence of the HIF-1α subunit, necessary
for HIF-1 activity, has been shown to increase exponentially in cells exposed to oxygen
levels lower than 6% [105 Jiang 1996b]. We have developed a transfer vector capable of
inserting a gene coding for production of a red fluorescent protein under the control of
HIF-1. In response to diminished oxygen availability, HIF-1α is upregulated, dimerizes
with HIF-1β, and attaches to HREs in the genome, initiating transcription of native
hypoxia response genes as well as the inserted red fluorescent protein gene. Signal can
be observed in living cells under a fluorescent microscope.
To better characterize this marker, we have employed it in PEG-encapsulated
murine β-cells. Covalently crosslinked PEG networks have been shown to provide a
suitable environment for β-cell survival [179 Weber 2006]. Among their favorable
characteristics, PEG hydrogels are highly biocompatible, non-degrading, and readily
functionalized. Within the hydrogels, hypoxia signal expression and cell function, as
defined by GSIS, were compared in normoxic and hypoxic conditions. As a rapid
indicator of hypoxia in living cells, we believe this detection system could prove useful
not only in cell encapsulation but also in other fields in which hypoxia plays an
important role, such as the directionalization of stem cell differentiation.
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2.3 Materials and Methods

2.3.1 Materials
PEG (linear, Mn = 10,000 g mol-1) and 1-Hydroxycyclohexyl phenyl ketone (99%)
(Irgacure 184) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used as
received. Methacrylic anhydride (94%) and reagent A.C.S. grade dichloromethane (≥
99.5%), and anhydrous diethyl ether (≥ 99.5%) were also purchased from Sigma-Aldrich
and used as received.

2.3.2 PEGDM Synthesis and Functional PEGDM Solution Preparation
Polymer was prepared in a manner similar to that described by Lin-Gibson et al.
[177 Lin-Gibson 2004]. Methacrylic anhydride and PEG were combined in a scintillation
bottle at a molar ratio of 10:1 by addition of 0.308g of methacrylic anhydride to 2.0g of
PEG. PEG was evenly melted by irradiating the bottle in a standard domestic microwave
(1050 W) for 2 minutes, vortexing, then irradiating for another 5 minutes. This process
allowed for covalent addition of a methacrylate group to each PEG chain end forming
PEGDM. The heated solution was allowed to cool briefly before being re-dissolved in
excess dichloromethane (~6 mL). PEGDM was precipitated out of solution in cold
anhydrous diethyl ether and collected by vacuum filtration. After drying, PEGDM was
dissolved in deionized water and transferred into cellulose ester dialysis tubing with a
molecular weight cut-off of 1,000 Da (Spectra/Por Dialysis Membrane, Spectrum
Laboratories, Los Angeles, California, USA). The solution was dialyzed against deionized
water for 5 days to purify the product. Water was replaced every 24 hours. After
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purification, the PEGDM solution was transferred into an appropriate container and
placed in a freezer at -80°C overnight. The frozen solution was then lyophilized on a
freeze-drier (Freezone 2.5, Labconco, Kansas City, MO, USA) for 4 days to obtain the
final powder form. To prepare the photoactive PEGDM solution, PEGDM was dissolved
in Hank’s Balanced Salt Solution (HBSS, Invitrogen, Carlsbad, CA, USA) to form a 10 wt%
solution. Irgacure 184 was added at 0.025 wt% as a photoinitiator. The final solution
was sterilized by filtration through a 0.2 μm syringe filter and stored in the dark.
Crosslinking was achieved by exposure of the desired volume of photoactive PEGDM
solution to long wavelength UV light (352 nm). Upon exposure, degradation of Irgacure
184 results in production of free radicals which attack the vinyl carbon-carbon double
bonds of the methacrylate end groups resulting in covalent crosslinking of PEG chains
and formation of the hydrogel.
In their work, Lin-Gibson et al. noted near stoichiometric conversion of PEG (Mn
= 1,000 and 4,000) to PEGDM after 5 minutes of reaction with methacrylic anhydride at
a 1:10 molar ratio (96% and 99% methacrylation, respectively, with no significant
difference) [177 Lin-Gibson 2004]. Initial monomer size was not observed to impact
resultant percent methacrylation.

The procedure described in our work for the

preparation and purification of PEGDM is identical to a similar procedure used by Weber
et al. for 10 kDa PEG monomers [179 Weber 2006]. Their group reports 95 ± 3%
methacrylation of PEGDM prepared by this method as determined by 1H NMR.
Byproducts of the microwave methacrylation reaction are methacrylic acid, which
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should be easily removed during purification, and un-methacrylated or monomethacrylated PEG which should only comprise a small percentage of the final product.

2.3.3 Cell Culture
MIN6 cells are an immortalized mouse pancreatic β-cell line exhibiting GSIS
comparable to native mouse β-cells.

Cells were cultured in RPMI 1640 medium

(Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillinstreptomycin (Invitrogen), and 0.5μg/mL Fungizone (Invitrogen). Cells were plated on
75 cm2 treated tissue culture flasks and incubated at ambient oxygen levels at 37°C and
5% CO2 in humid conditions.

2.3.4 Dissolved Oxygen Studies
Nitrogen-purged programmable incubators were used to maintain constant
oxygen levels for cellular studies (Napco Series 8000 WJ, Thermo Electron, USA). All
“high” oxygen studies were maintained at 5% CO2 and 20% oxygen. All “low” oxygen
studies were maintained at 5% CO2 and 1% oxygen. To determine the corresponding
dissolved oxygen content in culture medium during incubation, measurements were
taken with a dissolved oxygen probe (Pasport Xplorer GLX and Pasport Dissolved Oxygen
Sensor, PASCO, Roseville, CA, USA). The probe was calibrated with deionized water at
25°C. Then, 2 mL of RPMI 1640 growth medium was placed into the well of a 24-well
suspension plate, the probe was inserted, and the plate was incubated for at least 12
hours. The media remained uncovered and unagitated throughout study of both high
and low oxygen conditions. Incubator temperatures were maintained at 37°C. To
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determine if dissolved oxygen concentration was measurably impacted by cellular
utilization of oxygen, 1 million dispersed MIN6 cells were seeded into a well and allowed
to incubate in 2 mL of medium while dissolved oxygen concentration was measured.
Concentrations were again recorded for both high and low oxygen conditions.

2.3.5 Encapsulation of Cells
Cultures of MIN6 cells were trypsinized and counted with a hemocytometer on a
Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan). A range of densities were seeded
into 6-well suspension plates in a total volume of 2 mL of growth medium: 100,000
cells/mL, 300,000 cells/mL, and 500,000 cells/mL. Dissociated β-cells have been shown
to rapidly lose viability and function, but can spontaneously reaggregate if allowed [272
Matta 1994]. Therefore, cells were incubated at 37°C and 20% oxygen on a rotational
shaker at 100 rpm for 24 hours to allow for aggregate formation.
To prepared vessels for capsule polymerization, clear, 1mL syringes were placed
tip up in a rack and decapitated to remove the tapered point. Capsules were formed in
two steps. Bottom halves of capsules were prepared first, by addition of 20 μL of
photoactive PEGDM solution into the tips of standing syringes followed by
photopolymerization by UV irradiation for 10 minutes.

Then, cells that had been

aggregating for 24 hours were centrifuged at 200 rpm for 2 minutes and medium was
removed. Aggregates were re-suspended in 20 μL of photoactive PEGDM solution, with
care taken to not dissociate the aggregates. This volume was added into the syringe on
top of previously polymerized capsule bottom and polymerization was continued for an
additional 10 minutes.

In this manner, settling of suspended aggregates in their
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respective aliquot resulted in a finished capsule with aggregates fixed in the medial
plane. Finished capsules were cylindrical in shape, approximately 6 mm in diameter and
2 mm thick. Capsules were ejected from the syringe tubes, washed with HBSS, and
placed in 24-well suspension plates in 1 mL of growth media.

2.3.6 Characterization of Aggregate Sizes
Representative images of aggregates at Time 0 (initial time of encapsulation)
were analyzed for each of the three cell densities prepared using Nikon NIS-Elements
imaging software.

Long axis diameter and shortest orthogonal diameter were

determined. Average aggregate diameter and standard deviation were calculated from
long-axis measurements. A shape factor was also calculated as the ratio of the shortaxis to long-axis diameter for each aggregate. The number of aggregates determined to
be large (diameter > 150 μm) and extremely large (diameter > 250 μm) were
additionally determined and reported along with the average size of large and
extremely large aggregates.

2.3.7 Insulin Release Studies
To assess degree of device function, GSIS from encapsulated aggregates was
measured over two weeks.

Capsules containing 200,000, 600,000 and 1 million

aggregated cells were studied. One day after encapsulation, culture medium was
removed and 1 mL of a low concentration buffered glucose solution (1.1 mM) was
introduced to each well. Capsules were incubated for one hour before removal of this
solution and addition of a high concentration buffered glucose solution (16.7 mM).
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After an hour of incubation, samples from the high glucose solution were removed for
later analysis and capsules were returned to culture medium. These conditions were
used to replicate a starved-state/fed-state cycle. One set of capsules was then returned
to incubation in the high oxygen condition while the second set was placed in lowoxygen incubation. Glucose stimulation was repeated in this manner every 24 hours for
2 weeks. At the end of the study, insulin concentration in samples was determined via
mouse insulin ELISA assay (Mercodia, Upsalla, Sweden).

Capsules of each cellular

density were studied in identical experimental setups.

2.3.8 Construction of the Hypoxia Marker Virus
A schematic of the mechanism of hypoxia signaling is shown in Figure 2.1. The
marker virus is a recombinant adenovirus generated using the pAdEasy-1 system
(QBiogene, Montreal, Canada). The red fluorescent protein is a destabilized variant of
the DsRed protein. The destabilized protein (termed DsRed-DR) has a portion of mouse
ornithine decarboxylase fused to the C-terminus of the DsRed protein which contains a
PEST sequence. The DsRed-DR sequence was removed from its vector and inserted into
the multiple cloning site of the AdEasy transfer vector under the control of a minimal
SV40 promoter with a trimer of the HRE sequence from murine lactate dehydrogenase
(LDH). A transfer vector with the LDH HRE SV40 promoter was generously donated by
Dr. Rachel Cowen (University of Manchester, UK). The HRE trimer upstream of the SV40
promoter allows hypoxia-dependent transcription of the DsRed-DR protein.

After

insertion of the DsRed-DR sequence, the transfer vector was allowed to undergo
homologous recombination with the pAdEasy vector to produce the recombinant
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adenoviral genome which was linearized, transferred and amplified according to the
manufacturer’s specifications. Following purification of the virus, a plaque assay was
performed to determine the concentration of the resulting HRE DsRed-DR viral stocks
which allowed infection at specified multiplicities of infection (MOI). This value was
determined to be 3.7 x 107 plaque-forming units per microliter.

Figure 2.1 Schematic of a novel hypoxia detection system
in living MIN6 cells. In response to hypoxia, HIF-1α is
stabilized and dimerizes with HIF-1β. This unit initiates
transcription at HREs in target genes producing hypoxiaresponse proteins as well as the fluorescent DsRed-DR
protein.

2.3.9 Fluorescent Hypoxia Detection Studies
Cells were infected at an MOI of 100 by addition of the vector to the medium
just prior to the 24 hour aggregation incubation period. They were then encapsulated
as described in the methods and imaged on an inverted fluorescent microscope with an
excitation wavelength of 556 nm at a time denoted as Time 0. One set of capsules was
returned to the high oxygen condition while a second set was incubated in the low
oxygen condition. Capsules were then re-imaged approximately every 10 -12 hours for
2 to 3 days. Capsules containing 200,000, 600,000, and 1 million aggregated cells were
studied. Growth medium was replaced every 24 hours.
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2.3.10 Statistical Analysis
For capsules prepared at each of the described cell densities, mean insulin
secretion at the high and low oxygen conditions were compared. An unpaired Student’s
t-test assuming unequal variances and with α = 0.05 was used to determine significance
of differences between each condition. Significance of differences in size and shape
factor between groups was also determined by the same test. Some measured insulin
concentrations were at the maximum detectable limit of the performed assay. For
these samples, the maximum detectable value (an absorbance of 4.0 at 450 nm) was
used. Reported means calculated with inclusion of an estimated maximum value are
indicated by ’†’.

2.4 Results

2.4.1 Dissolved Oxygen
Dissolved oxygen concentrations in RPMI 1640 medium incubated in high and
low oxygen conditions overnight are shown in Figure 2.2A After 13.5 hours, medium in
the high oxygen condition exhibited a dissolved oxygen concentration of 3.9 mg/L. This
value was reached within the first 1.5 hours of incubation. Medium in the low oxygen
condition displayed a dissolved oxygen concentration of 0.6 mg/L after 13.5 hours while
showing a more gradual decline to this value. A dissolved oxygen concentration of 3.9
mg/L, which represents the end concentration reached in the high oxygen condition,
was reached within 15 minutes in the low oxygen trial.
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Figure 2.2 A) Dissolved oxygen concentrations measured in
2 mL of growth medium incubated at 37°C in 20% and 1%
oxygen. B) Dissolved oxygen concentrations measured in 2
mL of growth medium containing 1 million MIN6 cells
incubated in high and low oxygen conditions.

In the second trial, 1 million MIN6 cells were added to the media in both high
and low oxygen conditions. Figure 2.2B shows the dissolved oxygen concentrations
obtained from these trials. Media containing 1 million cells displayed a dissolved oxygen
concentration of approximately 4.0 mg/L after 13.5 hours in high oxygen incubation.
This showed no decrease from the value observed in the high oxygen condition in the
absence of cells. However, after 13.5 hours of low oxygen incubation, media containing
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1 million cells displayed a dissolved oxygen concentration of 0.2 mg/L. This value is
approximately one-third of the value observed for media free of cells in the low oxygen
condition.

2.4.2 Aggregate Sizes
Capsules were imaged immediately following polymerization to ensure that cells
were fully encapsulated and to determine the size of encapsulated aggregates.
Centrifugation and re-suspension of cells during the encapsulation procedure was not
observed to cause dissociation of aggregates. At each encapsulated density, the bulk of
aggregates had a diameter of 75-150 μm. At every density, at least one exceptionally
large aggregate (> 250 μm) was observed. These were more frequent in higher density
capsules, with 4 to 5 being observed in each capsule containing 1 million cells. Capsules
containing 1 million aggregated cells additionally displayed significant association of
averaged-sized aggregates to form larger fused aggregate networks.
Four representative images of encapsulated aggregates for each density were
analyzed to better characterize aggregate size. Table 2.1 shows average aggregate size
for aggregates formed at each of the seeded densities. The number and size of large
and exceptionally large aggregates are also given, along with average aggregate size
excluding large aggregates. Differences in average aggregate size between all groups,
though small, were found to be significant (p<0.05). When excluding aggregates larger
than 150 μm, which were less prevalent and displayed greater variability in size,
aggregates formed from 200,000 cells still displayed a statistically significant difference
in size from aggregates formed from 600,000 (p = 0.002) and 1 million (p = 0.0003) cells,
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though the differences in average size was small. Aggregates formed in the 600,000 and
1 million cell conditions did not display a significant difference in average size when
excluding large aggregates. In evaluating shape, aggregates were best described as
elliptical. Average shape factor was determined to be 0.72 and any difference in shape
factor among aggregates from different cell densities or between aggregates of
different sizes was not significant.

Table 2.1 Analysis of MIN6 aggregate sizes
Cell Density
(per capsule)

Size
( x , μm)

#>150
μm

%>150
μm

#>250
μm

200k
75.7*± 29.7
5
1.63
2
600k
80.1*± 33.4
9
1.67
2
1M
96.4*± 67.2
34
11.8
4
*Difference in value between groups is significant, p < 0.05.

%>250
μm
0.65
0.37
1.39

Size
( x , μm)
<150 μm
73.0*± 20.1
77.4*± 21.1
80.6± 30.0

Range (μm)
17.3-322.6
22.4-519.0
27.4-835.2

2.4.3 Glucose-Stimulated Insulin Secretion
GSIS was measured at high and low oxygen for each of the cell densities
prepared. In high oxygen conditions, capsules containing 200,000 aggregated cells
displayed an average (n = 4) insulin release of 6.4† μg/L (± 3.1 μg/L) at the end of two
weeks. Insulin release from capsules containing 600,000 (n = 3) and 1 million cells (n =
4) was reported on average to be 10.7 μg/L (± 0.9 μg/L) and 8.2† μg/L (± 3.2 μg/L),
respectively, at the end of two weeks. For all three high-oxygen trials, insulin release
remained relatively consistent and undiminished over the 14 day period. In 1% oxygen,
cells encapsulated at a density of 200,000 exhibited insulin release of 0.6 μg/L (± 0.4
μg/L), cells encapsulated at a density of 600,000 exhibited insulin release of 0.3 μg/L (±
0.1 μg/L), and cells encapsulated at a density of 1 million exhibited insulin release of 2.1
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μg/L (± 0.7 μg/L), after 14 days. In each case, drastic reduction in insulin release was
observed by as early as day 2. Figures 2.3A, B, and C show high-oxygen and low-oxygen
insulin release from capsules containing 200,000, 600,000, and 1 million aggregated
cells, respectively.

Figure 2.3 Daily one hour insulin release over 2 weeks from capsules containing (A)
200,000, (B) 600,000, and (C) 1 million aggregated MIN6 cells incubated in 20% or 1%
oxygen. Statistical significance of differences between high and low oxygen insulin
secretion values is indicated by ‘*’, where p < 0.05. Data points denoted by ‘†’ include at
least one estimated maximum value in determination of the mean.

Comparison of the low and high oxygen conditions showed no significant
difference in mean insulin secretion on Day 1 for all three trials. However, on Days 7
and 14, secretion in the low-oxygen condition was found to be significantly lower than
in the high-oxygen condition for each cell density tested. (p = 0.04 and 0.02, p = 0.01
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and 0.0008, and p = 0.03 and 0.02 for Days 7 and 14 for capsules containing 200,000,
600,000, and 1 million cells, respectively.)

2.4.4 Fluorescent Detection of Hypoxia
After incubation with the hypoxia marker vector for 24 hours, capsules
containing 200,000, 600,000, and 1 million aggregated MIN6 cells were incubated in
either high or low oxygen. Capsules were fluorescently imaged over 96 hours with red
signal indicative of hypoxic stress. For capsules incubated in high oxygen conditions,
signal was not detected in aggregates smaller than 250 μm over the three day study
period (Figure 2.4a1, b1, c1, d). Signal was observed in aggregates of all sizes within 20
hours in capsules incubated in low oxygen conditions (Figure 2.4a2, b2, c2). In both low
and high oxygen conditions, aggregates larger than 250 μm displayed signal in core
regions. With extended time, signal in low oxygen aggregates expanded to include the
entire aggregate, but remained localized in the aggregate core in high oxygen capsules
(Figure 2.4e, f). The largest aggregates (> 700 μm) exhibited localized interior signal at
the time they were encapsulated, immediately following the 24 hour aggregation period
(Figure 2.4 g). In continued hypoxic conditions, maximum signal expression was reached
by 48 hours and was sustained thereafter with maintenance of the low oxygen condition.
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Figure 2.4 Fluorescently imaged aggregates from capsules containing
200,000 (a, bar=100μm), 600,000 (b, bar=100μm), and 1 million (c,
bar=100μm) cells incubated in high (1) and low (2) oxygen conditions for 20
hours. At 20 hours in high oxygen, 250 μm aggregates (d, bar=100μm) did
not display signal, but 500 μm aggregates showed centralized signal (e,
bar=500μm). At 20 hours in low oxygen, 500 μm aggregates displayed
ubiquitous signal (f, bar=500μm), though signal onset also occurred in core
regions. Exceptionally large aggregates (~700 μm shown) displayed central
signal at Time 0 (g, bar=500μm). Fusion of smaller aggregates was noted in
capsules with higher cell densities (b1,c1,b2,c2).

2.5 Discussion
As early as 1980, transplanted encapsulated pancreatic tissue was shown to have
potential to alleviate diabetes [164 Lim 1980]. However, long-term success of such
devices has remained elusive, with oxygen insufficiency suspected as a primary cause.
Currently, most studies evaluating hypoxia in tissues do so indirectly, by quantifying
functional changes in response to varying oxygen levels, or after the fact by
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immunostaining fixed histological sections. However, the former approach does not
easily account for the fact that functional changes may not be exhibited uniformly by all
cells within a capsule, while the latter cannot indicate cellular responses at the time of
occurrence nor retain viability of the tissue of interest. On the other hand, knowing the
minimum cellular oxygen requirement, one could attempt to determine whether that
value is met within a capsule, as has been done with microelectrode measurement of
oxygen concentration [273 Carlsson 1998] and computational modeling [151 Gross
2007],[153 Buchwald 2009],[274 Dulong 2007]. However, although providing a good
estimate, models are time consuming to develop and employ and must be re-adapted to
any change in material or geometrical configuration. Furthermore, they still cannot take
into account every factor affecting oxygen concentration throughout a capsule as some
are not yet even fully understood. As an alternative approach, our fluorescent hypoxia
marker system allows individual, living cells to report when they initiate a hypoxic stress
response. This method both obviates the need to measure oxygen concentration and
allows hypoxic conditions to be detected quickly, and potentially remediated, prior to
tissue necrosis.
The hypoxia marker was evaluated in MIN6 aggregates encapsulated at different
densities within crosslinked PEGDM hydrogels. No toxic effects should be expected
from the method of encapsulation used in this work. Acrylated or methacrylated PEG as
an encapsulation matrix has been shown to be supportive of a range of cell types. PEG
itself is highly biocompatible while the Irgacure 184 photoinitiator has been shown to
have no influence on viability at low concentrations [180 Bryant 2000]. Bryant et al. also
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showed that 10 minutes of UV irradiation was likewise not detrimental to cell viability,
and report that this length of exposure is within the clinically acceptable range [180
Bryant 2000].

Low-speed centrifugation prior to encapsulation did not result in

aggregate disruption.
Results from both our functional studies and hypoxia detection studies are in
good agreement with the published literature. Exposure of MIN6 aggregates to hypoxic
conditions elicited an observable fluorescent response within 20 hours. Though future
work will focus on timing of signal initiation, extremely large aggregates (> 500 μm)
displayed central signal at the time of encapsulation. This indicates that signal onset
occurs fairly quickly and agrees with Moritz et al. who found that response to hypoxia
was observed in as little as 6 hours [275 Moritz 2002]. We also observed reduction in
insulin secretion under hypoxic conditions, with effects beginning as early as day 2.
Similar results have been widely reported [184 Dionne 1989],[185 Dionne 1993],[186 de
Groot 2003].
When comparing signal expression and insulin secretion between capsules
containing differing densities of cells, density of seeding did not appear to directly
influence hypoxic signaling; at 1% oxygen all aggregates appeared to display signal,
while at 20% oxygen signal was only seen in core regions of the largest aggregates. Thus
aggregate size appears to exert more influence over aggregate oxygenation than overall
cell number. As noted, though small, differences in average aggregate size between the
tested cell densities were determined to be significant. However, it is unlikely that
these average size differences contribute much to differences in signal expression and
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insulin secretion (73 μm and 80 μm aggregates, for instance, did not exhibit differences
in hypoxia signal expression and likely secreted insulin similarly). The percentage of
large and exceptionally large aggregates present in the differing populations, on the
other hand, may have contributed more significantly. In capsules containing 1 million
cells, aggregates 150 μm or larger represented nearly 12% of aggregates while making
up less than 2% of aggregates in 200,000- and 600,000-cell capsules. Additionally, twice
as many exceptionally large aggregates (>250 μm) were observed in 1 million-cell
capsules. At this size, aggregates began to display hypoxia signaling in core regions,
even in a 20% oxygen environment, again, consistent with findings by other groups [184
Dionne 1989],[275 Moritz 2002]. Thus, hypoxia signaling and insulin secretion were only
indirectly affected by seeding density in capsules containing 1 million cells, insomuch
that large aggregates were more prevalent. We point out that in our work it was
desirable to observe the behavior of both large and small aggregates. However, in
studies where stricter control of aggregate size may be important, consistency in size
may be achieved by aggregating cells at a density of 100,000 cells per mL and then
pooling aggregates to attain the desired number of cells per capsule.
Close observation of insulin secretion data may point to a tempting hypothesis –
a greater percentage of large aggregates with hypoxic core regions explains an apparent
“diminishing returns” in insulin secretion, where capsules containing 1 million cells
incubated in high oxygen secreted statistically similar amounts of insulin as capsules
containing 600,000 cells. Indeed, such an effect has been reported by Suzuki et al. [182
Suzuki 1998]. However, as noted, a number of the measured high-oxygen insulin
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concentrations were at the maximal detectable limit of the assay and were estimated in
calculations to be the maximal value. Because of this, accurate comparisons between
the different seeding density groups cannot be made. However, the effect of these
estimated values is not so detrimental to a comparison between the high and low
oxygen conditions, on which this study is primarily focused. Even with relatively large
standard deviation in some cases (attributable to small variability in cell number,
precision of the assay, and the nature of insulin secretion), cells in high oxygen
conditions secreted an amount of insulin that was, as calculated, significantly higher
than cells in low oxygen conditions on Days 7 and 14. Because any true secretion value
could only be the same or higher than the estimated value reported in this work, the
difference between levels of insulin secreted in high and low oxygen conditions would
only be increased by knowledge of the more accurate value. Thus our approach does
not impact any conclusion drawn by a comparison of the functional effects of a 20% or
1% oxygen environment.
We report that hypoxia signaling was observed within 24 hours of exposure to
low oxygen conditions while a drop in GSIS became apparent by day 2. In this sense,
hypoxic signaling was predictive of future device function. Furthermore, signal onset
was rapid enough to allow time for a remediating response prior to cell loss. Additional
study will be required regarding signal extinction, though preliminary observations show
that extinction occurs within 48 hours after re-exposure to the high oxygen condition.
We hope that with modification of MOI, this system may be tuned to achieve real-time
signaling. As a real-time indicator of hypoxia, the marker system might be particularly
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useful to study of encapsulated tissues in vivo. Strength of emission will determine if
signal is detectable, but we would expect utility at least in small animal models with an
implantation site near to the skin. A possible modification in order to increase in vivo
applicability could be to substitute a bioluminescent marker for the DsRed-DR gene used
in this work. Though quantification of either type of signal is difficult, current work is
focused on measuring HIF-1α levels to compare to fluorescent intensities and
determining threshold intensities corresponding to specific cellular responses.
Finally, though in this work MIN6 cells were particularly suited to demonstrating
our method of hypoxia detection, we believe that the marker system may be favorably
utilized in other cell types as well. We have recently, for instance, observed marker
expression in native islets of Langerhans isolated from Balb/c mice. In this regard,
degree of HIF-1 expression may vary among tissue types and will have large implications
as to whether the marker could be considered for use [275 Moritz 2002]. Nonetheless,
recent works suggesting the role of hypoxia in directing stem cell differentiation offer
another exciting field in which our method of hypoxia detection could be helpfully
employed [260 Abdollahi 2010],[276 Ma 2009],[277 He 2010]. We hope to investigate
such applications in future work.
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Chapter 3
Identifying HIF Activity in 3D Cultures of Islet-Like Clusters2

______________________________
M.L.. Skiles, N.B. Wilder, S. Sahai, J.O. Blanchette. Identifying HIF activity in threedimensional cultures of islet-like clusters. Int J Artif Organs 2013, 36(3);175.83.
(published) [278 Skiles 2013]

2
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3.1 Abstract
Purpose: Hypoxia is a major cause for failure of encapsulated islet grafts. 3D reaggregation and hypoxic preconditioning are used to help overcome this obstacle.
However, it is still difficult to identify hypoxic cells in a 3D system. We evaluate the
efficacy of a fluorescent system for detecting HIF-1 activity in live β-cells. Identification
of HIF-1 activity and correlation with insulin secretion and viability will allow for more
informed implant construction and better prediction of post-transplantational function.
Methods: MIN6 cells were infected with the marker virus and rotationally cultured to
form clusters. Clusters were encapsulated in PEG hydrogels and incubated in 20%, 2%,
or 1% O2. Gels were imaged daily for hypoxia marker signaling and for morphological
observation. Daily GSIS was quantified by insulin ELSIA and cell viability was assessed by
LIVE/DEAD staining.
Results: Clusters cultured in 2% and 1% O2 displayed high levels HIF activity compared
to 20% O2 clusters. 20% O2 clusters maintained viability and achieved a smooth, isletlike morphology by Day 14. Clusters in 2% and 1% O2 failed to associate cohesively and
showed reduced viability. As a whole, constructs cultured in 20% O2 exhibited 10-fold
higher GSIS than constructs in 2% and 1% O2.
Conclusions: Our marker is an effective approach for identifying cellular hypoxia in 3D
cultures. β-cell clusters in 2% and 1% O2 are similarly affected by reduced oxygen
tension, with HIF-1 activity correlating to reduced GSIS and impaired cell/cluster
morphology. Simultaneous aggregative culture and hypoxic conditioning may not be
beneficial to β-cell transplantation.
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3.2 Introduction
Cell-based therapies for treatment of T1DM remain hindered by dramaticallyreduced oxygenation of excised and transplanted islets [279 Davalli 1995],[280 Carlsson
2001],[281 Miao 2006]. While alleviating some of the difficulties associated with tissue
transplantation, encapsulation can further decrease oxygen tension in the graft [186 de
Groot 2003],[282 Cornolti 2009]. To reduce hypoxia-related loss of function, methods
such as hypoxic preconditioning [283 Semenza 2011b],[284 Lo 2012] and islet
dissociation/re-association (to produce smaller, more β-cell dense clusters) have been
suggested [191 Cavallari 2007],[285 Schuit 2001]. Still, further advancement in islet
transplantation will depend upon quick and accurate detection of the hypoxic state, an
understanding of the cellular impact of and response to hypoxia, and an ability to
remediate the hypoxic condition or avoid it in the first place.
Most cells exhibit substantial changes in gene expression as an adaptive
response to oxygenation below 5 or 6%.

A majority of these changes involve

upregulation of genes by activity of HIF-1, a heterodimeric bHLH-PAS family
transcription factor whose presence in the cell is tightly regulated by oxygen.
Specifically, the HIF-1α subunit is subject to rapid degradation under normoxic
conditions, but is exponentially stabilized as oxygen becomes limited [105 Jiang 1996b].
HIF responses serve to adapt the cell for survival in a low oxygen environment by,
among other things, switching the cell to glycolytic metabolism, promoting local
angiogenesis, inhibiting apoptosis, and reducing oxygen-intensive cellular activities [286
Cassavaugh 2011].

In the insulin-secreting β-cells of the pancreas, HIF-1-induced

81

switching to glycolytic metabolism has been shown to decouple glucose sensing from
insulin exocytosis resulting in a dramatic impairment of insulin secretion from hypoxic
islets [195 Zehetner 2008],[196 Cantley 2009],[197 Puri 2009].
Determining if and when insulin-producing cells become hypoxic is clearly
important in predicting their performance.

However, identifying hypoxic cells,

especially within 3D islet and islet-like cluster cultures, can be difficult. Measuring
oxygen partial pressure and modeling oxygen diffusion/consumption may help identify
regions of low local oxygen concentration but do not identify any behavioral changes in
the cells. A complimentary technique is to identify HIF-1 activity, which represents a
behavioral response to hypoxia whatever the specific oxygen concentration. Due to its
activity as a transcription factor and its short half-life (in normoxia, 4-8 minutes)
[109Moroz 2009],[287 Yu 1998], direct detection of HIF-1 without compromising the cell
and/or construct is difficult or impossible.

Furthermore, HIF responses are not

homogeneous across cell types, with degree of stabilization and upregulated target
genes varying between and within tissues [48 Maxwell 1993],[128 Brachen
2006],[129Lendahl 2009]. Therefore we employ a fluorescent reporter gene system
which indicates HIF activity in oxygen-stressed cells rather than HIF abundance. We
have previously reported the convenience of this approach for identifying hypoxic cells
in β-cell clusters and allowing HIF activity to be monitored in the same sample over time
[270 Skiles 2011a].
In the present work, we sought to compare HIF activity in aggregated,
encapsulated murine β-cells to other cell properties that are impacted by hypoxia, such
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as morphology, viability, and GSIS.

While atmospheric oxygen concentrations are

common in cell culture, they are not representative of an implant microenvironment;
therefore, we examined β-cell behavior in normal culture conditions (20% O2) as well as
a pair of more physiological oxygen concentrations commonly used for hypoxic
preconditioning (2% and 1% O2). Given the high oxygen requirement of β-cells, elevated
HIF activity would be expected to correlate to decreased insulin secretion and possibly
loss of viability. Such results would show the utility of the marker to predict functional
changes in encapsulated β-cells and to evaluate the consequences of various oxygen
conditions.

3.3 Materials and Methods

3.3.1 Cell Culture
MIN6 cells were cultured in RPMI 1640 medium (Mediatech, Manassas, VA)
supplemented with 10% fetal bovine serum (PAA, Dartmouth, MA), 1% penicillinstreptomycin (Mediatech), 0.5 μg/mL amphotericin B (Mediatech), and 7 mM D-(+)glucose (Sigma-Aldrich, St. Louis, MO). Cultures were maintained in standard incubation
conditions at 37 °C, 5% CO2, and high humidity. For experimental use, the cells were
trypsinized prior to confluence, counted, and seeded into the wells of a 12-well
suspension culture plate at a density of 400,000 cells per well in 1.7 mL of media.

3.3.2 Hypoxia Marker
For marker studies, the cells were infected with a hypoxia marker virus prior to
encapsulation, as previously described [270 Skiles 2011a]. Briefly, the marker virus was
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added to each well of dispersed cells at an MOI of 100 immediately following cell
trypsinization and seeding. The marker is a recombinant adenovirus generated by the
pAD-Easy-1 system (QBiogene, Montreal, Canada) that introduces a gene coding for a
destabilized variant of the red fluorescent protein, Ds-Red-DR under the control of a
minimal SV40 promoter and trimer of the HRE sequence. In an infected cell, hypoxiastabilized HIF-1 binds to the HRE and allows for hypoxia-induced transcription of the DsRed-DR gene and subsequent fluorescent signaling.
Following introduction of the virus, dispersed cells were incubated in rotational
culture at 100 rpm for up to 36 hours to allow for infection and for formation of isletlike clusters. Clusters were then encapsulated and immediately imaged, and the gels
were divided into three groups for rotational culture in either a 20%, 2%, or 1% oxygen
environment. Oxygen concentration was controlled through use of Napco Series 8000
incubators (Thermo Fisher, Waltham, MA) with automated nitrogen purging for
maintenance of a set oxygen percentage. Following placement in the appropriate
incubator, gels were fluorescently imaged daily followed by replacement of media.
As a positive control, cells were infected with a modified marker virus containing
a CMV promoter in place of the HRE trimer, allowing for constitutive expression of the
marker signal, regardless of oxygen status. As a negative control, uninfected cells were
also fluorescently imaged.
We have previously measured dissolved oxygen content of media incubated in
1% O2 and observed that 24 hour incubation is sufficient to achieve a steady,
equilibrated concentration [270 Skiles 2011a]. Therefore, in the present study, low-
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glucose media and high-glucose buffer solutions to be added to gels incubated in 2%
and 1% O2 conditions were pre-equilibrated to 2% and 1% O2, respectively, for 24 hours
prior to use.

3.3.3 PEGDM Synthesis and Cell Encapsulation
PEGDM was synthesized from linear, 10 kDa PEG (Sigma-Aldrich) as previously
described [270 Skiles 2011a], following a protocol adapted from Lin-Gibson et al. [177
Lin-Gibson 2004].

Briefly, microwave methacrylation of PEG was carried out by

irradiating a 10:1 molar ratio solution of methacrylic anhydride (Sigma-Aldrich) and PEG
in a standard domestic microwave for 5 minutes to form PEGDM. This was dissolved in
excess dichloromethane (Sigma-Aldrich) then precipitated in cold, anhydrous diethyl
ether (Sigma-Aldrich) and collected. The precipitate was dissolved in deionized water
and dialyzed against the same for 3 days for purification. Purified PEGDM powder was
collected by lyophilization.
A photoactive, PEGDM solution was prepared for the formation of hydrogels.
PEGDM was dissolved in HBSS (Mediatech) to form a 10 wt% weight solution and
Irgacure 2959 (Ciba, Basel, Switzerland) was added to 0.025 wt% as a photoinitiator.
The solution was sterile-filtered prior to use.
Cell clusters were encapsulated in a two-step process. First, the bottom half of
the hydrogel was formed by pipetting 20 μL of photoactive PEGDM solution into a
narrow cylindrical tube. The tube was exposed to UV light (365 nm, ~7 mW/cm2) for 8
minutes to initiate cross-linking. During this time, previously aggregated MIN6 clusters
were removed from their wells and centrifuged for 4 minutes at 210 g. The media was
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removed and the clusters were gently resuspended in 20 μL of photoactive PEGDM
solution. This volume was added on top of the first 20 μL volume and cross-linking was
completed by an additional 8 minute UV exposure. The hydrogels were then ejected,
rinsed in HBSS, and placed in a 24-well plate in 1 mL of media for incubation.

3.3.4 Glucose-Stimulated Insulin Secretion
To evaluate GSIS from encapsulated MIN6 clusters, gels were prepared with each
containing aggregates formed from a total of 400,000 cells. Freshly-formed gels were
divided into three groups and placed in 24-well plates in 1 mL of low-glucose media (2
mM) each. For the first day, all plates were incubated in rotational culture at 20% O2.
After 24 hours, the media was removed and replaced with a buffered, high-glucose
solution (16.7 mM) for one hour. This solution was removed and frozen for future
analysis and replaced with 1 mL of low-glucose media. Plates were then placed in
rotational culture at 20%, 2% or 1% O2. Thereafter, gels were stimulated in the same
manner every 24 hours. Insulin concentration in media samples was quantified by
mouse insulin ELISA (Mercodia, Winston-Salem, NC) following the manufacturer’s
protocol.

3.3.5 Viability
To assess viability of encapsulated cells, an esterase activity and plasma
membrane permeability assay (LIVE/DEAD, Invitrogen, Grand Island, NY) was performed.
MIN6 cells were aggregated and encapsulated as described and placed in 20%, 2% or 1%
oxygen incubation in 1 mL of media each. Every 24 hours, one gel from each incubator
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was removed and stained with LIVE/DEAD reagent for 30 minutes following the
manufacturer’s protocol. Media was replaced in the remaining gels and they were
returned to incubation.

Stained gels were then briefly rinsed with HBSS and

fluorescently imaged. Viable cells were indicated by a green cytoplasmic staining and
dead cells were indicated by red nuclear staining. For cells incubated in 2% and 1% O2,
media pre-equilibrated to 2% and 1% O2, respectively, was used.

3.3.6 Imaging and Statistical Analysis
Fluorescent imaging was performed on a Nikon Eclipse Ti (Nikon Instruments,
Melville, NY) inverted, fluorescent microscope. For fluorescent capture, care was taken
to ensure that consistent lamp intensity and exposure settings were maintained and
that fields were representative of the whole gel. In marker studies, the same gels were
tracked over time. Image analysis was performed in NIS-Elements AR 3.0 (Nikon)
software. For quantitative GSIS studies, a minimum of three replicate samples were
analyzed. Results are reported as mean ± standard deviation. Differences between
values were assessed by a student’s t-test assuming unequal variances with statistical
significance occurring when p < 0.05 (indicated in the results with an asterisk, ‘*’).

3.4 Results

3.4.1 Encapsulation and Cell Morphology
Clusters of aggregated MIN6 cells were formed by 36 hour rotational culture of
400,000 cells in low-adherence 12-well culture plates. Previous studies indicated that
clusters larger than 300 μm experience core hypoxia even at 20% oxygen conditions,
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and that few clusters of this size would be formed in rotational culture of 400,000 cells
[270 Skiles 2011a]. For each well, all clusters were collected and encapsulated in a
single hydrogel, placed in 20%, 2% or 1% oxygen conditions, and periodically imaged
over 2 weeks. Hydrogels were cylindrical, approximately 2 mm high and 5 mm in
diameter when swollen, with clusters distributed throughout (Figure 3.1).

Figure 3.1 400,000 MIN6 cells aggregated to form islet-like clusters and encapsulated in
a 40 μL PEGDM hydrogel. Bar = 1 mm.

Initially after formation, the cells were associated into small, irregularly-shaped
clusters with individual cells remaining discernable. By 4 days, 20% O2 clusters were
clearly distinguishable from Day 1 clusters, with Day 7 clusters displaying a more regular,
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ovoid shape and a smooth surface morphology akin to native islets. Individual cells
within the cluster could not be distinguished. In 1% or 2% oxygen, clusters did not
achieve a smooth, round morphology by 4, 7 or 14 days and individual cells were still βcells discernable within the clusters.

Clusters in 20% oxygen could be distinguished

from those in 1% or 2% oxygen by 4 days, though not sooner. After 2 weeks, clusters
incubated in 20% oxygen were large, round and healthy looking with a clear islet-like
appearance while clusters incubated in 2% and 1% oxygen appeared unchanged or
irregular and necrotic (Figure 3.2).
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Figure 3.2 Brightfield microscopy images of islet-like clusters for the
analysis of morphology over 2 weeks in 20% O2, 2% O2, or 1% O2.
Clusters incubated in 20% O2 attained a morphology similar to that of
primary islets by 1 week and retained that morphology thereafter.
Clusters incubated in 2% and 1% O2 never achieved a primary islet-like
morphology, with loosely associated cells and irregular aggregate
morphology.
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3.4.2 Hypoxia Marker
To correlate hypoxia with cellular activity of HIF-1, a fluorescent reporter system
was employed. Transient infection with the marker virus allowed the cells to produce a
red fluorescent protein under the control of active HIF-1. If present, this signal was
easily detected by fluorescent microscopy. At the time of encapsulation (Time 0), no
cells were observed to display fluorescent signal. At the given capture settings, Clusters
incubated in 20% oxygen exhibit few or no cells displaying fluorescent signal at the given
capture settings over the course of the study. Clusters incubated in 2% and 1% O2
showed a dramatic increase in number and intensity of fluorescing cells beginning on
Day 1 compared to 20% O2 clusters (Figure 3.3). Intense signal in 2% O2 slightly
preceded such signal in 1% O2. Maximum signal intensity was reached on Day 2 or 3.
Signal pervasiveness and intensity appeared similar between 2% and 1% O2 clusters.
Fluorescence was heterogeneous throughout signaling clusters, with signal clearly
identifiable in individual cells. Though signaling cells appeared somewhat randomly
distributed in the clusters, fluorescence was often observed in central cells of larger
clusters. In control studies, all CMV-DsRed-DR infected cells displayed rapid, intense
fluorescent signaling indicating efficacy of the system and high rate of infection.
Uninfected cells displayed no fluorescence.
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Figure 3.3 (Top) Schematic of HIF-induced cellular
fluorescence used to identify HIF activity in this
study. At sufficiently low oxygen concentrations,
HIF-1α is stabilized, dimerizes with HIF-1β and
binds to the HRE sequence, initiating transcription
of the target gene, in this case Ds-Red-DR.
(Bottom) Hypoxic signaling in islet-like clusters of
MIN6 cells infected with the hypoxia marker virus
for HIF-activated fluorescence. Clusters incubated
in 20% O2 displayed little or no fluorescence
through the study. Clusters incubated in 2% and
1% O2 expressed signal by Day 2 with fluorescence
located throughout all clusters.
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3.4.3 Glucose-Stimulated Insulin Secretion
We assessed the secretory activity of MIN6 clusters incubated in 20%, 2%, and
1% O2 for comparison to HIF-1 activity as indicated by the fluorescent marker. These
results are graphically represented in Figure 3.4.

Figure 3.4 GSIS in clusters of MIN6 cells cultured in 20%, 2%, or 1% O2
(mean ± standard deviation, n = 3). Large asterisks indicated significant
difference between 20% O2 and both low-oxygen conditions. Small
asterisks indicate significant difference between 2% and 1% O2 samples
(p < 0.05).

Consistent with islet-like morphological arrangement and minimal indication of
HIF-1 activity, clusters incubated in 20% oxygen displayed high levels of insulin secretion.
Continued increase in secretion was observed from Day 1 through Day 12.

This

correlates well with the timeframe over which primary islet-like size and morphology
were achieved. On Day 12 insulin secretion plateaued, with 37.8 ± 5.5 μg of insulin
secreted during the 1 hour stimulation period. In clusters incubated in 1% and 2% O2,
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very little increase in secretion from Day 1 was observed over the course of the study.
Statistical significance between secretion from 20% clusters and secretion from lowoxygen clusters was seen by Day 3, the time by which hypoxia signaling reached a
maximum. Secretion from clusters incubated in 2% O2 was slightly higher than secretion
from clusters incubated in 1% O2.

On Day 12, one-hour secretion from clusters

incubated in 2% and 1% O2 was measured to be 4.7 ± 0.2 μg and 4.1 ± 0.1 μg,
respectively, equating to 8 to 9 times less insulin than by clusters in 20% O2. As
reported, these secretion results represent the overall insulin-producing capability of
constructs incubated in their respective oxygen condition.

3.4.4 Viability
The viability of cells within the encapsulated clusters was examined via a
Live/Dead esterase activity/plasma membrane integrity assay (Figure 3.5). On Day 1,
nearly 100% viability was observed in cells from all three oxygen conditions. Cells
incubated in 20% O2 maintained this level of viability throughout the 14 day study. Loss
of viability in a small number of cells was first observed on Day 2 in gels incubated in 1%
oxygen and on Day 4 in gels incubated in 2% oxygen. Through the remaining two weeks
of the study, the appearance of non-viable cells slowly increased in both of these
conditions; however, overall viability appeared to remain high.
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Figure 3.5 Analysis of viability in clusters of MIN6 cells. Cells incubated in
20% O2 appear completely viable (green staining) over two weeks.
Clusters incubated in 2% and 1% O2 both displayed some cell death (red
staining, indicated with white arrows) within clusters by Day 4.
Numerous cells appeared to be non-viable in these conditions by Day 14,
though total viability was estimated to remain above ~75%.
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Consistent with morphological observations, green cytoplasmic staining,
indicating viable cells, expanded and intensified in 20% O2 clusters over the same
timeframe in which they adopted a primary islet-like morphology. That these clusters
were healthy and functional is supported by their high, sustained GSIS. Alternatively,
green cytoplasmic staining in 2% and 1% O2 clusters was unchanged or increasingly
diminished indicating a reduced cytoplasmic volume and reduced esterase activity. This
corresponded to both evidence of active HIF-1 and poor GSIS. Representative nonviable cells are indicated by the arrows in the figure. Though useful as an indicator of
change in viability between clusters incubated in 20% O2 and those incubated in hypoxic
oxygen conditions, percent viability within the clusters was not able to be accurately
quantified due to the 3D nature of the cultures and difficulty in distinguishing
neighboring cells.

3.5 Discussion
That low oxygen tension has a profoundly negative impact on insulin secretion
from pancreatic β-cells, both in vitro and in vivo, has been widely documented[184
Dionne 1989],[185 Dionne 1993],[186 De Groot 2003],[280 Carlsson 2001]. However,
the difficulty in assessing when a cell becomes hypoxic (i.e. begins to respond to
hypoxia) on a cellular level within 3D aggregates has hindered better understanding of
whether various physiological/culture conditions will illicit a detrimental hypoxic
response. Many common approaches to “identifying” hypoxia involve direct or indirect
measurement of oxygen partial pressure or dissolved oxygen concentration. However,
these methods suffer from a number of drawbacks, including invasiveness and potential
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tissue/construct

damage,

insufficient

resolution

for

cellular-scale

detection,

consumption of oxygen in the detection process, requirement for tissue/construct
sacrifice, reliance upon expensive equipment, and/or poor precision [288 Springett
2007],[289 Grist 2010]. Furthermore, these methods focus on measurement of oxygen
concentration but not cellular activity in response to that concentration.
Alternatively, the method discussed in this work identifies activity of the primary
regulator of intracellular response to hypoxia, HIF-1, and in this sense may be
considered to truly identify hypoxic status. This method has the added benefit that
signaling and detection do not impact viability and that the tissue/construct need not be
sacrificed in the detection process, as is required in histological analysis, allowing for the
same population to be examined over time. Our marker can be easily applied to
monolayer culture, micromass culture, and tissue culture within 3D scaffolds to
investigate the potential impact on oxygenation resulting from each of these conditions.
Furthermore, because the signal protein is a direct target of HIF-1, this system is ideal
for examining the relationship between culture conditions and various other HIFinduced responses.
HIF-activated pathways have been recognized as the primary mechanisms by
which low, intracellular, oxygen concentration is translated to a program of
transcriptional responses which result in loss of β-cell function.

We therefore

undertook the current work based on an interest in using identification of intracellular
HIF-1 activity as an indicator of activation of these downstream pathways.

We

employed a previously-developed fluorescent marker system to indentify HIF-1 activity
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in living cells which we compared to a number of physiological and functional events
known to be impacted by hypoxia. We showed that marker signal was induced by
hypoxic incubation and that signal corresponded to irregular cell association and
morphology, inability of clusters to achieve primary islet-like organization, and dramatic
decline in GSIS. Furthermore, hypoxic signal was apparent by Day 2, prior to the time at
which a difference in morphology of GSIS was detectable, highlighting the use of this
system as a predictor of cell viability and function.
Luther et al. report that unencapsulated clusters of MIN6 cells cultured in 20%
oxygen achieve a size and conformation similar to primary islets after 7 days [290 Luther
2005]. In the present study, we report that encapsulated MIN6 clusters achieve primary
islet-like size and appearance by Day 7 when cultured at 20% oxygen but not at 2% or
1% oxygen. Alternatively, MIN6 clusters incubated in 1% and 2% oxygen displayed
hypoxia marker signal expression, indicative of HIF activity, and failed to achieve the
tight, round morphology found in primary islets. Individual cells within the clusters
remained more distinguishable suggesting loose cell interactions rather than the tight
interactions seen in clusters at 20% oxygen. Proper function of pancreatic β-cells is
heavily dependent upon cell-to-cell contact [291 Hauge-Evans 1999],[292 Lin 2011],[293
Luther 2006]. HIF-1-induced repression of cell adhesion proteins such as E-cadherin
through upregulation of lysyl oxidase LOX, LOXL2, SIP1 and Snail provides an appealing
explanation for this poor association [294 Schietke 2010],[295 Evans 2007].
HIF-1 also impacts insulin secretion directly by hindering metabolic pathways
required for insulin exocytosis [283 Semenza 2011b].
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Secretion of insulin from

pancreatic β-cells is highly coupled to glucose sensing through aerobic mitochondrial
pathways [296 Lee 2008]. In β-cells with active HIF-1, these pathways are switched off
resulting in severely blunted GSIS.

We found that β-cell clusters incubated in

atmospheric oxygen conditions (20%) did not exhibit impaired GSIS, despite the
hindrances to oxygen diffusion that encapsulation and 3D tissues provide. However,
when cultured in low physiological levels of oxygen, the cells exhibited clear HIF activity
and impairment of GSIS in both 2% and 1% O2.
Current studies suggest that there may be benefits to dissociating islets and reforming them into islet-like clusters, primarily to reduce cluster diameter and improve
oxygen transport [285 Schuit 2001],[191 Cavallari 2007]. Indeed, large diameter clusters
can experience internal hypoxic gradients with central cells experiencing significantly
different oxygen conditions than peripheral cells. In previous studies, we reported that
central cells in clusters larger than approximately 300 μm displayed increased HIF
activity via the reporter gene, even in 20% O2 [270 Skiles 2011a]. Clusters smaller than
this size did not exhibit the increase in 20% O2 and exhibited more uniform HIF activity
in 2% and 1% O2. Thus it is likely that severe oxygen gradients are not developed in
clusters of the size examined in the current study. Another approach to improve posttransplantational function of β-cells is hypoxic preconditioning prior to implantation in
order to prime them for the reduced oxygenation of the implant site [283 Semenza
2011b],[284 Lo 2012]. Our results suggest that simultaneous aggregation and hypoxic
conditioning do not result in maintenance of islet-like morphology or GSIS and that the
two techniques should be applied individually or sequentially.
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3.6 Conclusions
It is clear that identifying cellular hypoxia will be beneficial to the advancement
of cell-based diabetes therapies. Our marker, indicating HIF-1 activity, represents an
ideal means of making such an identification. With this tool, we hope to establish
correlations between β-cell oxygenation in 3D systems and β-cell function. Having
shown its usefulness in a model system, we intend to apply this marker to future studies
in isolated mouse islets. Here, we will be able to make predictions about implant
function at various implantation sites with differing degrees of oxygenation. We will
also examine the correlations between HIF-1 activity, cell binding protein production
during re-aggregation, and GSIS in 3D culture systems. We feel that our marker system
represents a convenient, non-invasive method of indicating intracellular HIF-1 activity
that can serve as a much-needed tool for identifying hypoxia and examining its effects in
current and future cell-based delivery endeavors.
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Chapter 4
Use of Culture Geometry to Control Hypoxia-Induced VEGF Secretion from
ADSCs: Optimizing a Cell-Based Approach to Drive Vascular Growth3

______________________________
M.L. Skiles, S. Sahai, L. Rucker, J.O. Blanchette. Use of culture geometry to control
hypoxia-induced VEGF secretion from ADSCs: optimizing a cell-based approach to drive
vascular growth. Tissue Eng Part A (submitted, in revision)

3
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4.1 Abstract
ADSCs possess potent angiogenic properties and represent a source for cellbased approaches to delivery of bioactive factors to drive vascularization of tissues.
Hypoxic signaling appears to be largely responsible for triggering release of these
angiogenic cytokines, including VEGF. 3D culture may promote activation of hypoxiainduced pathways, and has furthermore been shown to enhance cell survival by
promoting cell-cell interactions while increasing angiogenic potential. However, the
development of hypoxia within ADSC spheroids is difficult to characterize. In the
present study we investigated the impact of spheroid size on HIF-1 activity in spheroid
cultures under atmospheric and physiological oxygen conditions using a fluorescent
marker. Hypoxia could be induced and modulated by controlling the size of the
spheroid; HIF-1 activity increased with spheroid size and with decreasing external
oxygen concentration. Furthermore, VEGF secretion was impacted by the hypoxic
status of the culture, increasing with elevated HIF-1 activity, up to the point at which
viability was compromised. Together, these results suggest the ability to use 3D culture
geometry as a means to control output of angiogenic factors from ADSCs, and imply that
at a particular environmental oxygen concentration an optimal culture size for cytokine
production exists.

Consideration of culture geometry and microenvironmental

conditions at the implantation site will be important for successful realization of ADSCs
as a pro-angiogenic therapy.
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4.2 Introduction
Therapies that stimulate regeneration of damaged tissues in the body or restore
deficient tissues with bioengineered replacements represent an appealing and emerging
technology. Such therapies often involve the implantation of cells or tissue into an
ischemic wound environment,

necessitating rapid vascularization for survival and

integration of the implant. Indeed, diffusional mass transfer limitations restrict the
potential size of engineered tissues and remain one of the biggest challenges to their
clinical success [201 Lovett 2009],[203 Novosel 2011]. New strategies to enhance
angiogenesis are required to overcome these hurdles.
Strategies that harness the angiogenic potential of cells have shown promising
results in recent studies. Fibroblasts [297 Levenberg 2005],[298 Kunz-Schughart 2006]
and mesenchymal stem cells (MSCs) [232 Kim 2007],[299 Blasi 2011],[300 Halfon 2011]
can significantly contribute to endothelial network formation and maintenance of
microvasculature. Dispersed mesenchymal stromal cells implanted in dermal wounds
[252 Lee 2009],[301 Nie 2011] and ischemic tissue [302 Kang 2010],[303 Bhang 2011]
increased local levels of angiogenic cytokines and promoted increased capillary density.
Of the potential cell candidates to be utilized for cell-based delivery, ADSCs appear
particularly well suited for use in regenerative medicine due to their relative abundance
and ease of culture as well as their ability to differentiate into relevant cell types in
musculoskeletal tissue engineering (e.g., osteoblasts, chondrocytes, vascular smooth
muscle cells).

103

The manner of cell transplantation to an injury site can impact transplant
performance. Cells injected as a dispersion have reduced cell-cell and cell-matrix
interactions which are important in sustaining pro-survival pathways and suppressing
apoptosis [265 Bates 2000],[303 Bhang 2011]. Alternatively, 3D cultures retain these
interactions, while also providing reduced oxygen tension within the cell mass which
may prime the cells for the ischemic implantation site [267 Bhang 2012a],[268 Saleh
2011],[269 Baraniak 2012], enhancing therapeutic effect. For example, cord blood
MSCs implanted as 3D spheroids upregulated expression of anti-apoptotic and
angiogenic proteins, downregulated expression of proapoptotic proteins, and showed
superior integration into newly forming vessels in ischemic mouse hind limbs compared
to dispersed cells [267 Bhang 2012a].
Oxygen gradients that form within 3D tissues are not necessarily detrimental. In
particular, hypoxia is responsible for initiating angiogenesis in vivo [304 Shweiki
1992],[305 Germain 2010] through activation of HIFs and subsequent upregulation of
bioactive factors such as VEGF [256 Forsythe 1996],[306 Maxwell 2002],[307 Fong
2009],[308 Rey 2010]. HIF proteins are dimeric transcription factors of the bHLH-PAS
family each composed of an α and β subunit [52 Wang 1995]. The α subunit undergoes
oxygen-dependent hydroxylation, marking it for proteosomal degradation. When local
oxygen concentrations are not adequate for hydroxylation to occur, the subunit is
stabilized, pairs with a β subunit, and is free to bind to HREs found in the promoter
region of a number of genes involved in adapting the cell for survival in low oxygen.
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Thus, oxygen tension in 3D cell masses can contribute to activation of HIFregulated pathways which benefit the cells. For instance, stabilization of HIF and VEGF
upregulation in growing avascular tumors is well known to promote tumor
vascularization [309 Brahimi-Horn 2001],[310 Semenza 2012b]. Similarly, endothelial
cells cultured as spheroids were found to express higher levels of HIF-1α mRNA than
those cultured as a monolayer under the same oxygen conditions [311 Bhang 2012b].
Additionally, hypoxia is known to play a role in regulating cell differentiation. During
formation of vascularized endochondral bone, regional hypoxia leads to HIF activation
and VEGF upregulation and is integral for the formation of a cartilage template and
synchronization of ossification with angiogenesis [312 Zelzer 2004],[313 Araldi 2010].
Thus it is clear that identifying approaches to regulate desirable, HIF-activated signaling
in ADSCs could provide new avenues towards creation of vascularized tissue and repair
of critical size defects in bone.
The present study investigates the ability to control VEGF secretion from ADSCs
by regulating hypoxic status. The effects of culture dimensions and incubator oxygen
tension (atmospheric conditions as well as a pair of hypoxic levels) on angiogenic
potential of ADSC spheroids are examined. HIF activity within the spheroids, identified
using a previously-described fluorescent marker system [270 Skiles 2011a], was
compared to levels of VEGF secretion from the cells. The impact of pelleting and
hypoxia on cell viability and morphology were examined by staining and histological
analysis. Results from this study provide insight into the nature of hypoxia in 3D
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cultures and may suggest a relevant approach for tailoring the release of angiogenic
factors from ADSCs for improved vascularization of engineered tissues.

4.3 Materials and Methods

4.3.1 Cell Culture
Passage 1 human ADSCs isolated from lipoaspirates were purchased from
Invitrogen (Carlsbad, CA) and cultured in Complete MesenPRO RS™ reduced-serum
medium supplemented with a penicillin-streptomycin solution (Mediatech, Manassas,
VA; final concentration: 115 IU/mL penicillin, 115 μg/mL streptomycin). This medium
was also used throughout all experiments.

For passaging, cells were kept in a

humidified atmosphere of 95% air and 5% carbon dioxide at 37°C.
changed three times a week.

Medium was

At approximately 80% confluence, the cells were

trypsinized and sub-cultured at a ratio of 1:4 until reaching passage 6, as recommended
by the supplier. All data included in these studies were obtained from cells between
passages 3 and 6. Maintenance of ADSC stemness was verified by cell-surface staining
and flow cytometry. Purchased, P1 cells were > 95% positive for stem cell surface
markers CD44 and CD105. Fluorescent antibody labeling for each (CD44: eBioscience,
San Diego, CA; CD105: Biolegend, San Diego, CA) revealed > 95% staining for both
markers at P6 (Figure 4.1).

106

Figure 4.1 Flow cytometry analysis of cell surface markers
CD44 and CD105 in P6 ADSCs. The cells were still >95%
positive for both markers at passage 6, indicating
maintenance of stemness.

Nitrogen-purged, programmable incubators (Napco Series 8000, Thermo
Electron, Waltham, Massachusetts) were used to maintain low oxygen levels for hypoxic
culture studies. For 2% and 1% oxygen studies, all media, buffers, and fixatives to be
used with the cells were kept in vented tubes in the corresponding incubator overnight
prior to use to equilibrate the solutions to the appropriate oxygen concentration.

4.3.2 Hypoxia Marker Virus
We have previously described the recombinant adenovirus used in this study to
identify HIF activity [270 Skiles 2011a]. Briefly, the virus was generated using the
pAdEasy-1 system (QBiogene, Montreal, Canada) by inserting into the vector a
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destabilized variant of the red fluorescent protein, DsRed, (termed DsRed-DR) under the
control of a minimal SV40 promoter and an HRE trimer. Previous ADSC studies have
indicated approximately 100% infection efficacy using an MOI of 80 (data not shown),
which was utilized in these studies.

4.3.3 ADSC Infection and 3D Culture Formation
At approximately 80% confluence, ADSCs were trypsinized, centrifuged,
resuspended in growth medium and counted. For HIF activity tracking studies, hypoxia
marker virus was added to suspended cells and gently mixed for 30 minutes. ADSC
spheroids of four different sizes were prepared by centrifugal pelleting. Five thousand
(5k), 10,000 (10k), 20,000 (20k), or 60,000 (60k) cells were pipetted into 0.5 mL, screwcap microcentrifuge tubes and centrifuged at 500 rcf for 2 minutes. Spontaneous
aggregation of the pelleted cells into cohesive spheroids occurred during overnight
incubation at 37°C. Spheroids of each size were then divided into three groups for
incubation in 20%, 2%, or 1% O2. While in incubation, the tube caps were loosened
slightly to allow for gas transfer. Medium was changed daily.
Spheroids for HIF activity tracking studies were encapsulated in polyethylene
glycol (PEG) by methods identical to those that have been published previously [270
Skiles 2011a]. For reference, a video demonstration of this method by the authors is
suggested [314 Skiles 2011b].
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4.3.4 Quantification of Secreted VEGF
For secretion studies, spheroids were cultured in a volume of media based on
cell number. 60k, 20k, 10k, and 5k spheroids were cultured in 900μL, 300μL, 150μL, and
75μL of medium, respectively. 60,000 cells grown in monolayer were also cultured at
each oxygen concentration in 1mL of medium.

Every 24 hours, the medium was

removed from each sample and replaced with fresh medium. Media samples were
stored at -80°C prior to analysis. Levels of VEGF in media samples were determined by
ELISA (Abcam, Cambridge, MA) following the manufacturer’s instructions. For each
group, 6 independent samples were analyzed.

4.3.5 Analysis of Cell Viability and Morphology
Cell viability in ADSC spheroids was examined using a LIVE/DEAD
cytotoxicity/viability assay (Invitrogen) and by histological examination. The LIVE/DEAD
kit was used according to the manufacturer’s instructions to identify esterase activity in
live cells and loss of plasma membrane integrity in dead cells. For histological analysis
of morphology, spheroids were first fixed overnight in a 4% paraformaldehyde solution.
The spheroids were then embedded in 2% agar, paraffin processed, and cut into 5μm
sections. Sections were stained with hematoxylin and eosin and imaged.

4.3.6 Fluorescent Cell Imaging and Image Analysis
Imaging for spheroid size determination and fluorescent detection of the hypoxia
marker was performed on a Nikon Eclipse Ti inverted fluorescent microscope (Nikon
Instruments, Melville, NY) and image processing and analysis was performed in NIS-
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Elements software (Nikon Instruments). Identical camera and microscope settings were
used for each capture within a study. Spheroids were imaged immediately following
encapsulation and then every 24 hours thereafter. Histological sections were imaged on
a Nikon Optiphot-2 microscope (Nikon) fitted with a Zeiss AxioCam MRc camera (Carl
Zeiss, Oberkochen, Germany).
For determination of spheroid sizes, the cross-sectional area of spheroids was
measured in the software from representative, central-plane images of spheroids from
each size group and the diameter of a circle with an equivalent area was calculated.
Results are reported as the mean ± standard deviation of 6 independent samples. To
roughly quantify hypoxia marker signal, a fluorescent signal threshold intensity was
applied to representative images from each group. The area of signal meeting or
exceeding the threshold value was compared to the total spheroid area as calculated
from the image. The threshold value was chosen such that no signal was detected in
monolayer cells incubated in 20% O2, as levels of HIF-1α in these cultures were below
detectable limits by western blotting in previous studies [315 Sahai 2012].

4.3.7 Statistical Analysis
All values are reported as mean ± standard deviation of replicate samples.
Statistical significance of differences between samples was determined by a two-tailed
student’s t-test assuming unequal variances (“**” indicates statistical significance at p ≤
0.01, “*” indicates statistical significance at p ≤ 0.05).
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5.4 Results

4.4.1 Pelleted ADSCs form Spherical, 3D Cultures of Reproducible Size
Following centrifugation, ADSCs formed a small plaque at the tip of each
microcentrifuge tube.

After overnight incubation, the cells had spontaneously

condensed into round spheroids with a diameter dependent upon the initial number of
cells.

Figure 4.2A shows representative spheroids of each size at Time 0.

ADSC

spheroids were cohesive and consistently sized within each group. In Figure 4.2B the
average diameter for spheroids from each study group at Time 0 (white bar) and at Day
4 (black bar) is shown. Minimum spheroid diameter was achieved by Day 4 with no
further condensation observed thereafter. 5k, 10k, 20k and 60k spheroids were 362 ±
10 μm, 454 ± 21 μm, 557 ± 20 μm, and 811 ± 37 μm in diameter, respectively,
immediately after formation. Spheroids diameters on Day 4 were 282 ± 6 μm, 379 ± 8
μm, 469 ± 16 μm, and 714 ± 15 μm, respectively. The ratio of spheroid size on Day 4 to
initial spheroid size was similar for all size groups, ranging from approximately 78% for
5k spheroids to 88% for 60k spheroids. Differences in culture oxygen concentration did
not appear to have an effect on spheroid condensation.
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Figure 4.2 Diameter of spheroids formed by centrifugally pelleting different numbers of
ADSCs. Initial spheroid size could be reliably controlled by adjusting the number of cells
pelleted (white bars). Spheroids continued to condense for several days following initial
formation before reaching a final minimal diameter by Day 4 (black bars). Bar = 500μm.

4.4.2 Spheroid Size and External O2 Concentration Affect Regional Hypoxic Signaling
The degree of HIF activity in ADSC spheroids as indicated by red fluorescent
signaling of the HIF marker is shown in Figure 4.3. In spheroids of all sizes, HIF activity
increased as incubator oxygen concentration decreased. With decreasing oxygen, signal
onset was more rapid and signal area and intensity were increased.

Signal also

increased with spheroid size. 5k spheroids incubated in 20% O2 displayed little or no
signal over 5 days. Increasingly more signal was seen in 20% O2 spheroids as spheroid
diameter increased. For each oxygen concentration, signal onset was more rapid and
signal area and intensity were higher as spheroid diameter increased. In general, signal
was first observed in central regions of the spheroids and remained most intense there.
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Figure 4.3 Fluorescent DsRed signaling as an indicator of HIF activity in 5k (top left), 10k
(top right), 20k (bottom left), and 60k (bottom right) ADSC spheroids incubated in 20%,
2% or 1% O2. The relative extent of signaling is quantified in the graph above each set of
figures by applying a signal intensity threshold value. The voided region caused by
spheroid condensation can be seen as a ring in the hydrogel around the culture in some
images. Bar = 500μm.
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To roughly quantify the prevalence of HIF activity throughout the spheroids, the
intensity threshold was applied to each image to identify regions exceeding it. The
areas of these regions were compared to the total spheroid cross-sectional area as
determined in the software (graphs in Figure 4.3).
The capture settings used in Figure 4.3 resulted in some spheroids with high
levels of HIF activity being overexposed. In this case, differences in signal intensity
between overexposed spheroids could be resolved by reducing the camera exposure
time (Figure 4.4). Though useful in identifying differences in HIF activity in spheroids
that exceeded the dynamic range of capture at the given settings, apparent signal
intensities measured from those images cannot be compared to intensities in Figure 4.3.
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Figure 4.4 Fluorescent HIF reporter signal displayed at 1/5 the exposure length as in
Figure 4.3 for 20k and 60k spheroids. Differences in signal intensity between samples
that were lost due to over-saturation are better resolved at the lower exposure.
Overexposure is still observed in 60k Day 3 and 4 spheroids. Bar = 500μm.
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4.4.3 Degree of Hypoxia Impacts VEGF Secretion Profile
Figure 4.5 displays per-cell VEGF secretion from ADSCs in monolayers and
spheroids cultured under different oxygen concentrations. The calculated mean values
and standard deviations are reported in Table 4.1.

Figure 4.5 Levels of daily and total per-cell VEGF release from ADSC monolayers and 5k,
10k, 20k, and 60k spheroids incubated for 5 days in 20%, 2%, or 1% O2.
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Table 4.1 Mean values and standard deviation of VEGF release
from ADSC cultures. Statistical significance of differences
between groups is indicated in Table 4.2.

Released VEGF values represent total release over the 24 hours prior to the
stated time point. For each culture size, cells secreted significantly more VEGF when
cultured in 2% or 1% O2 than in 20% O2, while little significant difference was observed
between 2% and 1% O2. In 2% and 1% O2 culture, monolayers and 5k spheroids
displayed significantly elevated VEGF secretion on Day 1 followed by a sharp decline
through Day 5. Under the same conditions, 10k and 20k spheroids displayed a much
more sustained elevation in VEGF secretion over 5 days, with peak secretion occurring
on Day 2. 60k spheroids showed minor elevation of VEGF secretion on Day 1 which
decreased over the remaining days. Total 5-day secretion was similar in 2% and 1% O2
culture, which were both significantly higher than 20% O2 culture. Total per-cell VEGF
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release increased from monolayers to 5k spheroids and from 5k to 10k spheroids then
decreased from 10k to 20k spheroids and from 20k to 60k spheroids.

Statistical

significance of differences in VEGF release between the different study groups can be
found in Table 4.2.

Table 4.2 Table indicating statistical significance of differences in mean VEGF release
from the cultures under study. ‘**’ indicates statistical significance at p ≤ 0.01. ‘*’
indicates statistical significance at p ≤ 0.05.
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5.4.4 Impact of Hypoxia on Morphology and Viability
The morphology of stained spheroid sections is shown in Figure 4.6a-h. On Day 1,
all spheroids appeared cellular and cohesive throughout (a-c). After 5 days of culture in
20% O2, little morphological change was observed in most spheroids, though 60k
spheroids did display a small central region of cells exhibiting cytoplasmic swelling (h).
In 2% O2, the region with cytoplasmic swelling in 60k spheroids was much larger and
some cellular discontinuity was observed (g). In 1% O2, the 60k spheroids exhibited
noticeable central tissue loss and a discontinuous core. Cells that did inhabit the central
region all expressed cytoplasmic swelling (f). The 10k and 20k spheroids cultured in 2%
and 1% O2 for 5 days exhibited only minor morphological changes in some central cells
but little or no loss of tissue. These spheroids cultured in 1% O2 are shown in Figures 4d
and 4e.
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Figure 4.6 a-h) H&E staining of ADSC spheroid sections. Immediately following
formation, spheroids showed high cellularity and cohesion (a-c). Cytoplasmic swelling
and loss of cellular cohesion (circled regions) of central cells increased significantly with
decreasing culture oxygenation in 60k spheroids (f-h). 10k and 20k spheroids incubated
in 1% O2 for 5 days showed little morphological change, though cellular discontinuity
was seen in a small central region of some 20k spheroids (d & e). Inset: i-l) Live/Dead
viability assessment of ADSCs in 5k (i), 10k (j), 20k (k), and 60k (l) spheroids cultured at
1% O2 for 4 days. Green fluorescence indicates a viable cell while red, nuclear
fluorescence indicates a non-viable cell. Bar = 500μm.

A LIVE/DEAD viability stain showed that on Day 1, no dead cells were observed in
5k, 10k, and 20k spheroids and only a small number were observed in 60k spheroids. As
seen in Figure 4i-l, on Day 4 no dead cells were observed in 5k spheroids and only a
small number of dead cells were observed in 10k spheroids. 20k and 60k spheroids
displayed relatively more non-viable cells, though these still appeared to represent a
small percentage of overall cells. All dead cells were located in peripheral regions of the
spheroids.
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4.5 Discussion
In this work, we examined the degree of HIF activity in ADSCs cultured as
spheroids of different sizes in atmospheric and reduced-oxygen conditions. We found
that HIF activity increased in spheroids in a size-dependent manner and with decreasing
culture oxygenation. As a well-defined HIF target, we expected VEGF to be secreted at
levels that increased correspondingly with HIF activity. VEGF release profiles could be
altered by changing the spheroid size, with 10k spheroids cultured in 2% or 1% O2
secreting most efficiently. That spheroids larger than 10k secreted VEGF less efficiently
despite having greater HIF activity may be due in part to loss of cell viability as hypoxic
severity increases, as is supported by the histology. Our results indicate that culture
geometry can be used a means to control cell function and stress the need to carefully
consider tissue size and expected oxygen concentration at the implant site when
engineering a therapeutic graft in order to maximize the benefits of HIF-activated
pathways.
The majority of studies in 3D stem cell cultures are carried out in atmospheric
oxygenation or under a single “hypoxic” oxygen level (often 1% or 5% O2) and examine
only a single culture size. We suspected that differences in culture size and external
oxygen concentration (even within the hypoxic range) would significantly impact culture
oxygenation and in turn affect cellular function.

To test this, we prepared ADSC

spheroids in a range of sizes and cultured them in three different oxygen concentrations.
Centrifugal pelleting resulted in rapid formation of cohesive and spherical cultures while
providing a high degree of control over spheroid size. Additionally, a wide range of sizes
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could be produced (including spheroids both larger and smaller than those reported in
this study). Culture size was highly reproducible and only dependent on the number of
cells in the initial suspension.
HIF activity was monitored within the spheroids over 5 days. As the master
regulator of transcriptional responses to low oxygen conditions, HIF activation may be
the most meaningful indicator of cellular hypoxia [48 Maxwell 1993]. Tracking HIF
activity rather than oxygen concentration/distribution, as in other techniques [316
Revsbech 1983],[317 Krihak 1996],[318 Acosta 2007], provides evidence of a behavioral
response. This is useful, as the oxygen concentration required to trigger a behavioral
effect can vary between cells or even within the same cell under different
microenvironmental conditions [126 Chi 2006],[319 Gibbs 2012]. With our HIF marker,
image capture settings could be adjusted to match observed signal with quantified HIF-1
levels.

Furthermore, it allowed for non-invasive identification and localization of

hypoxia in cells within the 3D cultures and could follow HIF activity in the same sample
over time without requiring its sacrifice. Hydrogel encapsulation facilitated consistency
in repeated imaging of the same sample. While the hydrogel capsule can alter oxygen
diffusion to some degree, the nature of qualitative trends observed between spheroids
of different sizes were not affected. We saw that reduced oxygenation resulted in
increased transcriptional activity of HIF-1 in spheroids and that increasing spheroid size
amplified this effect. Quicker onset and increased intensity of fluorescent signaling was
observed as culture size increased and external oxygen concentration decreased.
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These results are in line with other studies: HIF-1 was shown to be exponentially
stabilized in monolayer cultures as oxygen concentration decreased from 6 to 0.5% [105
Jiang 1996b], and higher protein levels of HIF-1α were observed in ischemic mouse limb
buds implanted with spheroid cultures rather than dispersed HUVECs [311 Bhang
2012b]. Similarly, small ADSC clusters (100-200μm) were shown to contain higher
protein levels of HIF-1α than monolayer ADSCs in both 20% and 1% O2 [303 Bhang 2011].
Our studies provided evidence on transcriptional activity of HIF-1 and examined a range
of larger spheroid sizes (350 - 800 μm) that better represent the size of cultures
commonly prepared in osteochondral tissue engineering.
Because of the potential for a capsule to impact diffusion, spheroids for VEGF
secretion studies were not encapsulated. Our results indicated that VEGF release is
impacted by both external oxygenation and spheroid size, with VEGF profiles differing as
these two parameters were altered. In 1% and 2% O2, 10k spheroids appeared to
provide optimal secretion. Compared to cultures incubated in 20% O2, 60k, 20k, 10k,
and 5k spheroids and monolayers incubated in hypoxic conditions O2 showed an
approximate 1.5, 3.5, 5.5, 2.5, and 2.5-fold increase in VEGF production per cell,
respectively. However, in our HIF tracking studies, 20k and 60k spheroids displayed
greater HIF activity than 10k spheroids. We suspect that this is due to the severity of
hypoxia occurring within these spheroids, especially in the spheroid core.

Severe

hypoxia is known to result in a rapid and dramatic reduction in protein turnover,
inhibiting protein translation and transduction [28 Hochachka 1996],[320 Pettersen
1986],[321 Koumenis 2002]. Additionally, sudden, severe hypoxia can trigger apoptotic
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pathways or even result in cellular necrosis [322 Greijer 2004],[323 Kiang 2006],[324
Burton 2009]. Results from our nuclear dye exclusion assay indicated few non-viable
cells, even in 60k spheroids cultured at 1% O2. However, histological examination
revealed significant acellularity and evidence of necrosis in these spheroids.

This

interior cell death indicates severe central hypoxia and offers an explanation for the
lower than anticipated VEGF secretion from 60k and 20k spheroids.
Taken together, our data suggests that the profile of VEGF release from a 3D
ADSC spheroid is the result of a balance between two opposing effects of hypoxia: 1)
Decreased oxygen tension resulting from cellular oxygen utilization and diffusional
limitations stabilizes HIF-1 and induces upregulation of VEGF. 2) Excessive hypoxic
tension, such as increasingly occurs in the interior of spheroids as size is increased, can
lead to global protein down-regulation and cell death. ADSCs have demonstrated proangiogenic potential and may represent a preferential source for cell-based delivery in
tissue engineering and regenerative medicine. Furthermore, the benefits of 3D culture
are recognized. Considering culture geometry and expected environmental oxygen
concentration allow for optimization of angiogenic function of 3D ADSC cultures and will
be essential to balancing the beneficial and detrimental effects of hypoxia to achieve
their successful utilization in tissue engineering and regenerative medicine.
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Chapter 5
Conclusion
Although oxygen tension is a potent signaling stimulus in cells, it often remains
unconsidered in experiments carried out under standard culture conditions. However,
to drive restorative function of transplant tissues in vivo, proper in vitro application of
physiological cues that contribute to regulating cell behavior will be needed.

In

particular, physiological oxygen concentrations are well below the atmospheric
concentration, in a range that is often viewed as hypoxic in relation to standard culture
practices. Within this range, HIFs govern cellular responses to local reductions in oxygen
concentration. These responses can result in down-regulation of typical cell functions
and programmed cell death, or alternatively, stimulation of adaptive behaviors involved
in beneficial processes such as growth, differentiation, and repair.

However,

surprisingly few cell transplantation and tissue engineering efforts consider the role of
HIF activity in tissue function, even though the intended therapeutic site is a
physiological environment within the body. Due to its ability to regulate cell behavior,
cell therapies may benefit from a view that treats oxygen as similar to other paracrine
factors: a biomolecule that must be presented to cells at the proper concentration in
order to illicit the intended response.
particular

oxygen

concentration

can

However, because specific responses to a
be
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cell-type

and

context

dependent,

HIF activity may represent a more reliable indicator of microenvironmental oxygen
conditions that affect cell behavior. In the present work, a fluorescent reporter system
was used to identify HIF activity in cells and demonstrate how an understanding of HIF
activity can be used to instruct decisions that affect the therapeutic potential of
different cell transplantation strategies.
HIF activity was characterized in encapsulated, 3D β-cell clusters and in 3D ADSC
spheroids. Transplantation of encapsulated β-cells is a regenerative medicine therapy
aimed at restoring normoglycemia in patients with T1DM through secretion of insulin
from the transplanted tissue which is protected from immune destruction by the
encapsulating material. To maintain important cell-to-cell contacts which contribute to
β-cell survival and secretory function, β-cells are often transplanted as native, 3D islets
or as reaggregated islet-like clusters. Lack of vascularization, low oxygenation at the
implant site, and oxygen gradients resulting from the 3D nature of the tissues and the
protective capsule have all been suggested to contribute to hypoxia-induced loss of
function in such therapies. ADSCs have been applied in regenerative medicine therapies
to help restore ischemic tissue injuries. ADSCs have potent angiogenic properties that
are upregulated under hypoxic conditions. 3D, spheroid culture of ADSCs may modulate
their hypoxic status and contribute to their survival through cell-cell interaction.
Inclusion of ADSC spheroids in in vitro engineered tissues or in vivo regenerating tissues
may contribute to the formation of a pro-angiogenic niche within the tissue which could
help drive rapid vascularization and assist tissue integration and survival. Both of these
therapies offer the promise of improved outcomes in patient. Each also demonstrates a

127

role for hypoxia in the success of the therapy.

In β-cell encapsulation and

transplantation, cellular hypoxia should be avoided in order to prevent HIF-regulated
loss of insulin secretion, while when using ADSCs to drive angiogenesis, promotion of
hypoxia can contribute to upregulation of HIF-regulated, pro-angiogenic behaviors. The
ability to identify HIF activity within cells in each of these systems can guide culturing
and engineering decisions in order to optimize their therapeutic potential.
The use of a fluorescent reporter system to identify HIF activity in β-cells or
ADSCs has not been reported previously. The present studies indicate that the reporter
is a viable and useful tool for determining the hypoxic status of cells used in
regenerative therapies. β-cells and ADSCs cultured in 1% and 2% O2, conditions under
which HIF should be stable, exhibited fluorescent signaling indicating HIF transcriptional
activity. Cells cultured as monolayers in 20% O2, conditions under which HIF should not
be stable, did not exhibit fluorescence. Compared with other methods commonly used
to identify HIF, such as Western blotting and immunostaining, the reporter technique
was favorable because it allowed for repeated observation of HIF activity over time.
Additionally, the fluorescent signal could be observed through PEGDM matrices,
meaning that encapsulated cells did not need to be removed from the capsule in order
for HIF activity to be examined.
HIF activity, indicated by the reporter, correlated well to differences in behavior
between signaling and non-signaling tissues. HIF activity in β-cell clusters corresponded
to much lower GSIS than in clusters that did not display HIF activity.

Recently-

aggregated β-cell clusters that displayed fluorescent signaling also failed to achieve a
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cohesive, islet-like morphology over time, while non-signaling clusters gradually became
smooth and round, much like native islets. Surprisingly, HIF activity did not appear to
correspond to a substantial drop in viability in β-cell clusters over 2 weeks. In ADSC
spheroids, increased HIF activity corresponded to an increase in VEGF secretion,
although spheroid size also appeared to indirectly effect VEGF secretion by affecting
regional cell survival. Intense fluorescent signaling corresponded to the appearance of
pre-apoptotic or necrotic morphologies in large spheroids.
Using the HIF reporter system in 3D tissue cultures also provided information
about how tissue size affects the formation of oxygen gradients within the tissue, and
allowed for regional identification of heterogeneous HIF activity.

β-cell clusters

incubated in 20% O2 that were smaller than 250-300μm did not display fluorescent
signaling. However, larger clusters displayed HIF activity in their central region in 20%
O2, which increased in size as cluster size increased to maintain a signal-free peripheral
region of consistent thickness.

Likewise, onset of fluorescent signaling in ADSC

spheroids occurred in central regions.
Finally, results from the present studies offer instructive suggestions about the
design decisions for β-cell and ADSC transplantation therapies. In β-cells, large clusters
displayed central regional HIF activity. Thus, it may be beneficial to utilize clusters that
are smaller than 250μm in order to avoid hypoxia-induced loss of function. Additionally,
1% O2 culture induced strong HIF activity and reduced GSIS which was not remediated
by an increase in oxygen concentration within the hypoxic range to 2% O2. Therefore
strategies to ensure implant-site oxygenation of >2% could be beneficial to the success
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of β-cell therapies. Finally, incubation in low oxygen conditions did not allow for normal
morphological arrangement of recently-aggregated β-cell clusters. This suggests that
reaggregation and hypoxic preconditioning techniques should not be employed
simultaneously in β-cells. In ADSC, external oxygen concentration and culture size were
both shown to contribute to pervasiveness of HIF activity in spheroids. Increasing
spheroid size and decreasing external oxygenation could both be used to augment HIF
activity. Moderate elevation of HIF activity was shown to correlate to an increase in
VEGF secretion per cell, however, very high levels of HIF activity correlated to increased
cell death which reduced secretion efficiency.

This suggests that for a desired

application, optimal cell function can be driven by careful selection of culture
parameters to effect hypoxic status. In the study, 400μm spheroids were shown to
produce VEGF most efficiently. This is the first report to show that tissue size can be
used to optimize cell-based delivery of angiogenic factors from ADSCs. Overall, then,
the studies reported in this work point to the important ways in which oxygen tension
can affect cell behavior in cell transplantation therapies and highlights the usefulness of
the fluorescent HIF reporter system. Conclusions from these studies, and others which
may utilize HIF tracking, should be instructive in guiding the use of appropriate
physiological stimuli in tissue engineering and regenerative therapies to drive optimal
restorative function.
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6. WILEY shall have the right to terminate this Agreement immediately upon breach of this
Agreement by you.
7. You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach of this
Agreement by you.
8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY
OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE
DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH
THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS
REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF
CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT
OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON
LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF
THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED
REMEDY PROVIDED HEREIN.
9. Should any provision of this Agreement be held by a court of competent jurisdiction to
be illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as
nearly as possible the same economic effect as the original provision, and the legality,
validity and enforceability of the remaining provisions of this Agreement shall not be
affected or impaired thereby.
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10. The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition of
this Agreement. No breach under this agreement shall be deemed waived or excused by
either party unless such waiver or consent is in writing signed by the party granting such
waiver or consent. The waiver by or consent of a party to a breach of any provision of this
Agreement shall not operate or be construed as a waiver of or consent to any other or
subsequent breach by such other party.
11. This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
12. Any fee required for this permission shall be non-refundable after thirty (30) days from
receipt

�

13. These terms and conditions together with CCC s Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all
prior agreements and representations of the parties, oral or written. This Agreement may not
be amended except in writing signed by both parties. This Agreement shall be binding upon
and inure to the benefit of the parties' successors, legal representatives, and authorized
assigns.
14. In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC s Billing and Payment terms and conditions,
these terms and conditions shall prevail.

�

15. WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing transaction,
(ii) these terms and conditions and (iii) CCC s Billing and Payment terms and conditions.

�

16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type
was misrepresented during the licensing process.
17. This Agreement shall be governed by and construed in accordance with the laws of the

�

State of New York, USA, without regards to such state s conflict of law rules. Any legal
action, suit or proceeding arising out of or relating to these Terms and Conditions or the
breach thereof shall be instituted in a court of competent jurisdiction in New York County
in the State of New York in the United States of America and each party hereby consents
and submits to the personal jurisdiction of such court, waives any objection to venue in
such court and consents to service of process by registered or certified mail, return receipt
requested, at the last known address of such party.
Wiley Open Access Terms and Conditions

164

Wiley publishes Open Access articles in both its Wiley Open Access Journals program
[http://www.wileyopenaccess.com/view/index.html] and as Online Open articles in its
subscription journals. The majority of Wiley Open Access Journals have adopted the
Creative Commons Attribution License (CC BY) which permits the unrestricted use,
distribution, reproduction, adaptation and commercial exploitation of the article in any
medium. No permission is required to use the article in this way provided that the article is
properly cited and other license terms are observed. A small number of Wiley Open Access
journals have retained the Creative Commons Attribution Non Commercial License (CC
BY-NC), which permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.

�

Online Open articles
Authors selecting Online Open are, unless particular exceptions
apply, offered a choice of Creative Commons licenses. They may therefore select from the
CC BY, the CC BY-NC and the Attribution-NoDerivatives (CC BY-NC-ND). The CC BYNC-ND is more restrictive than the CC BY-NC as it does not permit adaptations or
modifications without rights holder consent.
Wiley Open Access articles are protected by copyright and are posted to repositories and
websites in accordance with the terms of the applicable Creative Commons license
referenced on the article. At the time of deposit, Wiley Open Access articles include all
changes made during peer review, copyediting, and publishing. Repositories and websites
that host the article are responsible for incorporating any publisher-supplied amendments or
retractions issued subsequently.
Wiley Open Access articles are also available without charge on Wiley's publishing
platform, Wiley Online Library or any successor sites.
Conditions applicable to all Wiley Open Access articles:
•

The authors' moral rights must not be compromised. These rights include the right
of "paternity" (also known as "attribution" - the right for the author to be identified
as such) and "integrity" (the right for the author not to have the work altered in such
a way that the author's reputation or integrity may be damaged).

•

Where content in the article is identified as belonging to a third party, it is the
obligation of the user to ensure that any reuse complies with the copyright policies
of the owner of that content.

•

If article content is copied, downloaded or otherwise reused for research and other
purposes as permitted, a link to the appropriate bibliographic citation (authors,
journal, article title, volume, issue, page numbers, DOI and the link to the definitive
published version on Wiley Online Library) should be maintained. Copyright
notices and disclaimers must not be deleted.

� Creative Commons licenses are copyright licenses and do not confer any other
rights, including but not limited to trademark or patent rights.
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•

Any translations, for which a prior translation agreement with Wiley has not been
agreed, must prominently display the statement: "This is an unofficial translation of
an article that appeared in a Wiley publication. The publisher has not endorsed this
translation."
Conditions applicable to non-commercial licenses (CC BY-NC and CC BY-NCND)
For non-commercial and non-promotional purposes individual non-commercial
users may access, download, copy, display and redistribute to colleagues Wiley
Open Access articles. In addition, articles adopting the CC BY-NC may be adapted,
translated, and text- and data-mined subject to the conditions above.
Use by commercial "for-profit" organizations
Use of non-commercial Wiley Open Access articles for commercial, promotional, or
marketing purposes requires further explicit permission from Wiley and will be
subject to a fee. Commercial purposes include:
o

Copying or downloading of articles, or linking to such articles for further
redistribution, sale or licensing;

o

Copying, downloading or posting by a site or service that incorporates
advertising with such content;

o

The inclusion or incorporation of article content in other works or services
(other than normal quotations with an appropriate citation) that is then
available for sale or licensing, for a fee (for example, a compilation
produced for marketing purposes, inclusion in a sales pack)

o

Use of article content (other than normal quotations with appropriate
citation) by for-profit organizations for promotional purposes

o

Linking to article content in e-mails redistributed for promotional, marketing
or educational purposes;

o

Use for the purposes of monetary reward by means of sale, resale, license,
loan, transfer or other form of commercial exploitation such as marketing
products

o

Print reprints of Wiley Open Access articles can be purchased from:
corporatesales@wiley.com
The modification or adaptation for any purpose of an article referencing the
CC BY-NC-ND License requires consent which can be requested from
RightsLink@wiley.com .
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Other Terms and Conditions:
BY CLICKING ON THE "I AGREE..." BOX, YOU ACKNOWLEDGE
THAT YOU HAVE READ AND FULLY UNDERSTAND EACH OF THE
SECTIONS OF AND PROVISIONS SET FORTH IN THIS AGREEMENT
AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING
TO ACCEPT ALL OF YOUR OBLIGATIONS AS SET FORTH IN THIS
AGREEMENT.

v1.8
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Dear Dr Skiles,
According to the copyright regulations applied by IJAO, authors retain the
following rights:
Retained rights
Provided the source is fully quoted at all times, Authors are hereby granted the right to:
a) reproduce the manuscript in whole or in part in any printed book or thesis of which
they are the author(s).
b) They and any academic institution where they work at the time may reproduce the
Manuscript in a reasonable number of copies for the
purpose of course teaching. This does not apply if a commercial charge is made for the
training course.
c) To post a copy of the Manuscript as accepted for publication after peer review (in
Word or Text format) on the Authors’ website provided that
they also link to the article to the Journal’s web site.
d) To reuse figures or tables created by them and contained in the Manuscript in other
works created by them.

You may therefore proceed with your dissertation.
With kind regards,
Lucia Steele
Lucia Steele
Permissions
Wichtig Editore Srl | Via Friuli 72 | 20135 Milan (Italy)
Office +39 025455122 ext. 24
Mobile +39 3939129472
lucia.steele@wichtig.it | Skype: luciasteele62

168

